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Abstract 
Galectins are beta-galactoside animal lectins which possess similar carbohydrate recognition 
domains and have important roles in the development and regulation of innate and 
adaptive immunity. Galectins have been previously shown to modulate inflammatory 
responses to bacterial infections, however nothing is known about the functions of different 
galectins during meningococcal disease. 
Here I describe the interaction between galectins, in particular galectin-3, and Neisseria 
meningitidis, a commensal of the human respiratory tract that occasionally causes 
septicaemia and meningitis. Immunohistochemical analyses showed that expression of 
galectin-3, but not galectin-1 and galectin-8, is increased in tissues of mice following 
challenge with N. meningitidis; furthermore, galectin-3 staining co-localises with the 
bacterium in tissues from patients with meningococcal disease.  
The molecular basis of interaction between N. meningitidis and exogenous galectin-3 was 
investigated by identifying both the bacterial structures and the regions of galectin-3 
involved. Binding of galectin-3 to N. meningitidis was shown to be dependent on bacterial 
lipopolysaccharide (LPS), while inhibition assays with lactose and the use of truncated 
versions of galectin-3 demonstrated that the C-terminal carbohydrate recognition domain is 
necessary, but not sufficient, for the interaction. Furthermore, the biological consequences 
of interaction of bacteria with galectin-3 were investigated. Exogenous galectin-3 did not 
affect adhesion of N. meningitidis to epithelial cells, but increased the attachment of 
bacteria to phagocytic cells; silencing of galectin-3 expression in phagocytes did not alter the 
interaction of N. meningitidis with cells. 
In summary, galectin-3 binds to N. meningitidis via LPS and affects meningococcal 
interaction with phagocytic cells. The potential role of galectin-3 in pathogen recognition is 
discussed. 
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CHAPTER 1: Introduction 
 
1.1 History of meningococcal disease 
Neisseria meningitidisis a human specific, Gram negative coccus which colonises 
approximately 10% of the healthy population, with the human nasopharynx its sole 
reservoir (Cartwright et al. 1995). This bacterium is one of the leading causes of bacterial 
meningitis worldwide (Hill et al. 2010). 
Meningococcal disease was probably first described by Vieusseux in 1805 in Geneva, 
who reported a “non-contagious malignant cerebral fever” which was fatal in a few hours 
and attributed to a “special constitution of the air” (Vieusseux 1805). After Vieusseux’s 
description, there were several reports of a disease with similar symptomson both sides of 
the Atlantic during the 19th and 20thcenturies. The meningococcus was isolated in the 
19thcentury from the cerebrospinal fluid (CSF) of patients with meningitis by Weichselbaum 
(Weichselbaum 1887).The mortality rate for untreated meningococcal disease was between 
75-80 % (Swartz 2004), and was only reduced following the production of a meningococcal 
antiserum (Flexner and Jobling 1908). The serum was initially prepared by injecting live and 
killed bacteria into horses, and the first trial in humans was performed in the 1908; overall 
mortality rates fell from 80% to 30% with treatment (Flexner and Jobling 1908). In the 
1930s, the mortality associated with meningococcal disease decreased further with the 
introduction of sulphonamides (Feldman 1972). Furthermore, preventive measures against 
N. meningitidis have been available since the development of the first vaccine in 1969 
(Goldschneider et al. 1969b).Despite these advances, N. meningitidis infection continues to 
be a major public health problem worldwide. 
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1.2 Classification of N. meningitidis: genetic and serological typing 
To date, 13 serogroups of N. meningitidis have been identified, on the basis of 
antigenically distinct polysaccharide capsules (Hill et al. 2010). Strains can also be 
distinguished by variation in other antigens including surface proteins and 
lipopolysaccharide (LPS) (Kuipers et al. 2001). For example, differences in the structure of 
meningococcal LPS determine immunotypes. Immunotypes L8, L9, L10 and L11 are generally 
expressed by serogroup A strains, whilst immunotypes L1 through to L9 are associated with 
serogroup B and C strains, the most prevalent being L3, 7, 9 (Verheul et al. 1993). 
As surface antigens of N. meningitidis can alter through antigenic or phase variation 
(Martin et al. 2004), alternative typing techniques have been implemented. N. meningitidis 
can be divided into clonal complexes by multi-locus enzyme electrophoresis (MLEE) or 
multi-locus sequence typing (MLST) (Caugant et al. 1986; Maiden et al. 1998). MLEE is based 
on the electrophoretic mobility of abundantmetabolic enzymes. However, MLEE is not used 
routinely because of a lack of reproducibility (Tibayrenc 2009; Harrison et al. 2011). In 
contrast, MLST is basedon differences in the nucleotide sequence of seven genes encoding 
housekeeping functions (Maiden et al. 1998). Disease causing strains can be grouped into 
clonal complexes based on their genetic similarity, either as electrophoretic (ETs) or 
sequence types (STs). 
 
1.3 Epidemiology 
There are approximately 1.2 million cases of invasive meningococcal disease each 
year around the world, with around 135,000 deaths (Bai et al. 2011). Meningococcal disease 
14 
 
affects individuals of all ages, and the serogroups commonly associated with disease are A, 
B, C, W135, X and Y ((Panatto et al. 2011) and Fig. 1.1). 
Certain serogroups are associated with particular epidemiological features. Strains of 
serogroups B and C cause the majority of infections in industrialized countries, while 
serogroups A and C strains dominate in third world countries (Stephens et al. 2007). Most of 
the disease in Africa is caused by serogroup A meningococci (Halperin et al. 2011). 
Historically, serogroups A and C have caused epidemic disease and pandemics in Africa, Asia 
and South America (el-Akkad 1969); serogroups X and W-135 have also caused outbreaks in 
Africa (Trotter and Greenwood 2007). In particular, sub-Saharan Africa has been designated 
the “meningitis belt”, first described in 1963, as it contains the countries from Senegal to 
Ethiopia (Molesworth et al. 2002).The epidemiology of meningococcal disease in this area is 
characterised by seasonal and epidemic waves (Tall et al. 2012). Most epidemics of 
meningitis have been caused by serogroup A strains, although serogroups W135 and X have 
caused disease in the last decade (Boisier et al. 2006; Mueller et al. 2006; Collard et al. 
2010). Major serogroup B epidemics occurred during the second half of the 20th century in 
Iceland, Norway, Turkey and Cuba as well as other countries (Racloz and Luiz 2010). 
However, serogroup B still causes the overwhelming majority of endemic meningococcal 
disease in Europe and the USA, and can cause prolonged epidemics (Cohn et al. 2010).In 
addition, an increase in serogroup Y disease was also reported in Europe and the USA during 
the last decade (Hedberg et al. 2011). 
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From the “Canada communicable disease report”, 2009 
Figure 1.1 Meningococcal serogroups associated with disease in different countries. 
Disease caused by serogroups B, C and Y are frequent in the Americas, Europe and Australia, 
while disease caused by serogroup A is more frequent in Africa and Asia. Epidemics of 
serogroup W-135 disease can occur in Africa. 
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1.4 Pathogenesis of meningococcal infection 
N. meningitidis is an inhabitant of the human nasopharynx, and occasionally crosses 
the mucosal barrier and enters the bloodstream (Perrin et al. 2002). Colonisation of and 
passage through the epithelial barrier are crucial first steps in the invasion process, and type 
four pili (Tfp) and outer membrane proteins (OMPs) are involved in initial meningococcal 
adhesion (Corbett et al. 2004). Tfp are filamentous glycosylated structuresextending from 
the bacterial surface, whichtraverse the capsular polysaccharide.They have beenproposed 
to bind membrane co-factor protein, CD46 (Kallstrom et al. 1997). Meningococcal 
attachment can trigger changes in cortical actin of epithelial cells, leading to neisserial 
uptake (Rytkonen et al. 2004). Further contact with the host cells is established through the 
class 5OMPs, Opa and Opc. Opa binds to carcinoembryonic antigen CD66,while Opc binds to 
heparan sulphate proteoglycan receptors (HSPGs), resulting in bacterial engulfment by 
epithelial cells and transcellular traversal (Virji et al. 1994). Interestingly, passage into the 
bloodstream is reduced by the presence of capsuleor sialylated LPS, factors that are crucial 
for survival of meningococci in the bloodstream (Vogel et al. 1996). During carriage and 
invasion, the expression of class 5 OMPs, pili, LPS and capsule issubject to phase switching 
and/or antigenic variation (Nassif and So 1995; Hammerschmidt et al. 1996). 
N. meningitidis can enter non-ciliated respiratory epithelial cells and reach the 
submucosa, or directly invade damaged epithelial surfaces (Capecchi et al. 2005). At this 
point, binding of pili and Opa proteins to host receptorsis responsible for signal transduction 
in host cells,resulting in maturation of lysosomesand facilitatingbacterial invasion (Hauck 
and Meyer 2003). Subsequently, bacteria reach the systemic circulation wherethey replicate 
and survive through expression of bacterial virulence factors andsubverting host immunity. 
Within the bloodstream, meningococci induce a marked inflammatory response, 
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activatingthe complement and coagulation cascades. This leads to fever with or without 
septic shock (Tzeng and Stephens 2000). 
A key inducer of the inflammatory response is LPS, which results in meningococcal 
septic shock (Plant et al. 2006; Fransen et al. 2010) and interacts with Toll like receptor-4 
(TLR-4) leading to the production of pro-inflammatory cytokines (Zimmer et al. 
2007).Induction of cytokine expression in the vasculature results in endothelial damage and 
capillary leakage (de Kleijn et al. 1998), leading to necrosis of tissues and multiple organ 
failure (Brandtzaeg et al. 1989a). There is a clear correlation between circulating levels of 
LPS and the severity of disease (Brandtzaeg et al. 1989a). In general, bacteraemia is not 
always followed by meningitis, but the vasculature is still considered the primary route of 
infection to the central nervous system (CNS)(Mikaty et al. 2009).In some cases, bacteria 
reach the meninges leading to meningitis. The blood CSF barrier is formed by two 
structures: the choroid plexus, situated in the ventricles and composed of cuboidal epithelial 
cells joined by tight junctions, and the capillary endothelium (Fan et al. 2012). Adhesion of 
bacteria to the endothelium is dependent on the flow rate and shear stresses imposed by 
the blood flow (Soyer and Dumenil 2011). The route of bacterial passageacross this barrier is 
unclear, but pili and other adhesins may have similar functions here as with epithelial cells. 
However, although pilus-mediated adhesion of N. meningitidis to epithelial and endothelial 
cells is followed by the formation of an identical cortical plaque (which is a molecular 
structure formed by actin, adhesion molecules and membrane receptors crucial for 
adherence), different mechanisms for bacterial interaction have been proposed for these 
cell types (Lecuyer et al. 2012).How piliated bacteria cross endothelial cells to enter the 
meninges is unclear (Nassif et al. 1999), but one hypothesis is that intracellular signalling 
induced by Tfp leads to the disruption of intercellular junctions at the site of bacterium-cell 
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interaction, enabling bacterial passage(Coureuil et al. 2009). Once in the subarachnoid 
space, meningococci promote the production of pro-inflammatory cytokines resulting in 
meningitis, oedema, apoptosis and ischaemia (Rosenstein et al. 2001). 
 
1.5 Host susceptibility to meningococcal infection 
The factors that contribute to meningococcal disease and epidemics are not fully 
understood. However, they include the immune status and susceptibility of the host, 
bacterial characteristics and environmental factors.The lack of protective bactericidal 
antibodies in individuals is an important factor,but host genetic polymorphisms also 
contribute (Goldschneider et al. 1969b; Brouwer et al. 2009). Specifically, polymorphisms in 
genes encoding the Fcγ-receptor II (CD32), Fcγ-receptor III (CD16), mannose binding lectin 
(MBL), factor H and TLR-4 have been associated with meningococcal disease (Emonts et al. 
2003; Brouwer et al. 2009). Genome wide association studies highlighted that genetic 
variation in regulators of complement activation,including factor H, contributes to host 
susceptibility to meningococcal disease (Davila et al. 2010). 
A functional complement system is necessary to prevent meningococcal disease; 
individuals lacking components of the membrane attack complex (MAC) have an increased 
risk of developing disseminated meningococcal infection compared to normal individuals 
(Kuijpers et al. 2010). Deficiencies or dysfunction of properdin are associated with invasive 
or severe meningococcal infection (Nielsen et al. 1989), while factor D deficiency also 
predisposes to meningococcal infection (Sprong et al. 2006).  
Deficiency of MBLhas been associated with N. meningitidis infection, although only in 
early childhood (Emonts et al. 2003; Faber et al. 2007), and clinical studies have shown that 
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MBL deficiency can be associated with bacterial infection in patients with neutropenia and 
meningococcal sepsis (Eisen and Minchinton 2003). 
 
1.6 Neisseria meningitidis virulence factors 
N. meningitides is able to evade immune defences by varying its surface structures or 
by mimicking host molecules (Hill et al. 2010),and expresses numerous virulence factors that 
promote bacterial survival in the human host (Fig. 1.2).  
 
1.6.1 Polysaccharide capsule 
The capsule polysaccharide has an important role in the interactions between the 
pathogen and the host. Capsules of serogroup B, C, Y and W-135 strains (which cause the 
most cases of disease) contain sialic acid (5-N-acetyl-neuraminic acid, NANA). The capsule 
biosynthesis genes are clustered in a chromosomal locus called the cps. The genes siaA, siaB 
and siaC are responsible for the synthesis of sialic acid; siaD encodes for a poly sialyl 
transferase involved in capsule polymerisation (Edwards et al. 1994). 
The serogroup B capsule is formed by an α-(2-8)-linked sialic acid homopolymer 
which has identical structure to a modification on a human neural cell adhesion molecule, 
N-CAM1 (Finne et al. 1987) and is a clear example of molecular mimicry which enables 
meningococci to avoid recognition by the host immune response. In addition, the serogroup 
B capsule is chemically similar to the capsule of K1 strains ofEscherichia coli (Frosch et al. 
1991). The capsular polysaccharide promotes resistance against antibody/complement 
mediated killing and inhibits phagocytosis (Kahler et al. 1998). In particular, high levels of 
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capsule expression can inhibit complement mediated lysis in the presence of bactericidal 
antibodies that are specific for PorA or are raised against the capsule itself (Uria et al. 2008). 
Furthermore, the meningococcal capsule promotes bacterial survival in intracellular 
compartments, possibly by protecting bacteria against cationic antimicrobial peptides 
(CAMPs) (Spinosa et al. 2007). 
Interestingly, meningococci which are isolated from carriers can be capsulated but 
are more often non-encapsulated, while meningococci which are isolated from blood or CSF 
of patients are almost always encapsulated (Andersen 1989). 
 
1.6.2 Lipopolysaccharide (LPS) 
Meningococcal LPS consists of a variable, surface exposed saccharide region and a 
more conserved lipid A portion that anchors the molecule in the bacterial outer membrane. 
Meningococcal LPS is subject to variation of terminal structures and for example its 
sialylation depends on the growth conditions including the presence of cytidine-5’-
monophospho-N-acetyl-neuraminic acid (CMP-NANA) (Schmiel et al. 2011). The surface 
exposed polysaccharide region consists of up to 10 monosaccharides butlacks an O-antigen, 
typical of the LPS of some Gram negative bacteria(Samuel and Reeves 2003). 
The 12 immunotypes of meningococcal LPS are distinguished on the basis of a 
combination of sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE) analysis and the 
use of rabbit antisera and monoclonal antibodies (Tsai et al. 1987). Strains can express more 
than one immunotype-specific epitope, defining the classification of the strains as L3,7,9, 
L2,4 or L1,8 for example (Verheul et al. 1994). However, there are no monoclonal antibodies 
available for several other immunotypes. 
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Lipid A consists of two β-1-6 linked glucosamine residues containing α-glycosidic and 
non-glycosidic phosphorylgroups at the 1 and 4 positions, and (R)-3-hydroxy fatty acids in 
ester and amide linkages (Alexander and Rietschel 2001). Meningococcal lipid A is linked to 
a conserved inner core region consisting of two heptose (HepI and HepII) residues, attached 
via a 3-deoxy-D-manno-2-octulosonic acid (Kdo) residue (Fig. 1.3). Meningococcal LPS is very 
similar to LPS of the closely related pathogen Neisseria gonorrhoeae that only differs in its β-
chain which contains a different number of saccharide residues. The Lacto-N-neo-tetraose 
(LNnT) is present in the LPS from both species, and is attached to HepI via a glucose (Glc) in 
meningococcal LPS, while in the gonococcus it is attached to HepI via a N-acetyl-
galactosamine (GalNAc) and a galactose (Gal) residue (Fig. 1.3, A and B). 
Immunotypes differ in their monosaccharide composition, type of linkage between 
sugar residues, amount and location of phospho-ethanolamine (PEA) groups and degree of 
acetylation. Lipid A can be modified with one or multiple PEA groups at the 4’ position by 
the PEA transferase LptA (Cox et al. 2003). HepII is invariably substituted by an N-acetyl 
glucosamine (GlcNAc) residue and PEA groups can be attached to HepII by the PEA 
transferases Lpt6 and Lpt3 (Mackinnon et al. 2002; Wright et al. 2004).Addition of a glucose 
residue can occur at the 3 position by the LgtG α 1,3-glycosyl transferase (Banerjee et al. 
1998),(Fig. 1.3). 
While the inner core structure is common to most immunotypes, the LNnT epitope is 
only found in L2, L3, L4, L5, L7, L8 and L9 immunotype LPS (Tsai et al. 1998). The L3,7,9 
immunotype strains can switch to L8 immunotype strains by phase variation of the lgtABE 
locus; this results in the termination of the α-chain after the first Gal residue (Jennings et al. 
1995b; Jennings et al. 1999). LnNT is also present in host paragloboside, a precursor of 
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group blood antigens and some human sialylated glycosphyngolipids (gangliosides) (Macher 
and Klock 1980).  
The LNnT can be sialylated on the terminal Gal residue,and this can modify epitopes 
recognised by monoclonal antibodies and have an impact on the interaction with the 
immune system.The Lst α-2,3 sialyl transferase catalyses the linkage of sialic acid to the 
LNnT epitope, using CMP-NANA synthesised by the meningococcus or obtained from the 
environment (Tsai 2001).  
LPS sialylation modulates susceptibility to bactericidal antibodies, phagocytosis and 
down regulatescomplement activation (Vogel et al. 1997). Furthermore, meningococcal 
adhesion and invasion of epithelial cells is inhibited by LPS sialylation (Virji et al. 1994) and 
resistance to killing by polymorphonuclear leukocytes (PMNs, neutrophils) correlates with 
the extent of LPS sialylation as well as encapsulation (Estabrook et al. 1992).  
Meningococcal LPS has a pivotal role in septicaemic disease and septic shock,by 
inducing expression of cytokines (with Tumour necrosis factor-α, IL-6 and IL-1 being the 
most abundant), activating the complement system and increasing plasminogen activator 
inhibitor levels (Hellerud et al. 2008). Once infection is established, this marked host 
inflammatory response to LPS contributes to the mortality and morbidity associated with 
meningococcal disease (Brandtzaeg et al. 1989b; Brandtzaeg et al. 2001). 
LPS, as well as intact or degraded bacteria and outer membrane vesicles, are highly 
biologically potent. LPS activates immune cells via TLR-4 and this depends on the lipid A 
moiety of LPS (Jerala 2007). LPS binding protein (LBP) and CD14 facilitate engagement of the 
co-receptor MD2 (Fitzgerald et al. 2004), forming a complex on macrophages, monocytes 
and neutrophils (Jerala 2007). The clustering of TLR-4 and recruitment of adaptor proteins 
triggers intracellular signalling, leading to the activation of nuclear factor kappaB (NFkB) and 
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other transcription factors that induce cytokine production. NFkB migrates to the nucleus 
and initiates the transcription of genes encoding various inflammatory mediators such as IL-
1β and TNF-α ((Akira and Takeda 2004) andFig. 1.4). 
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Figure 1.2 Major meningococcal surface structures 
Schematic representation of the meningococcal outer membrane containing the principal 
surface exposed proteins responsiblefor virulence of the bacterium. The periplasm is 
between the outer and inner membranes (OM and IM) and contains the peptidoglycan cell 
wall. OMPs include the two porins PorA and PorB, opacity proteins (Opa and Opc).The Tfp 
extends beyond the other protein structures, traverses the OM and reaches the IM. LPS is 
indicated.  
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Figure 1.3 Schematic structure of meningococcal and gonococcal LPS. 
(A)Structure of meningococcal LPS, immunotype L3,7,9.Genes encoding enzymes responsible for the 
addition of sugars and the glycosidic linkages (lst, lgtB, lgtA, icsB) and epimerases (galE) are 
indicated.(B) Structure of gonococcal LPS. Key: NeuNAc, N-acetylneuraminic acid; Kdo, 3-deoxy-D-
manno-2-octulosonic acid; Hep, heptose; Glc, glucose; GlcNAc, N-acetyl-glucosamine; Gal, galactose; 
PEtn, phospho-ethanolamine; N-acetyl-lactosamine (LacNAc); Lacto-N-neo-tetraose (LNnT).  
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Modified from Akira et. al 2004 
Figure 1.4 NF-kB signalling pathways dependent on TLR-4 activation. 
Recognition of pathogen associated molecular patterns (PAMPS) by TLR-4 triggers 
dimerisation, interaction with the co-factor MD-2 and the binding to CD14. The MyD88 
signalling pathway involves the early phase NFkBactivation whichleads to the production of 
pro-inflammatory cytokines and the late phase NFkB activation, which leads to production 
of Interferon-β (IFN-β) and expression of IFN-inducible genes. 
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1.6.3 Type IV pili 
An important step in the pathogenesis of N. meningitidis infection is the adhesion of 
bacteria to epithelial cells in the nasopharynx. This initial step of colonisation is mediated by 
type IV pili (Tfp) (Hill et al. 2010). Pili are dynamic organelles that undergo cycles of 
extension and retraction (Carbonnelle et al. 2006); they are filamentous protein structures 
on the surface of bacteria and are composed of repeating pilin protein subunits of 
approximately 17 to 21 kDa each (Parge et al. 1995). Neisserial pilins belong to typeIV pilins 
that are found in diverse bacterial genera such as Moraxella, Pseudomonas and Vibrio 
(Nassif and So 1995). The major pilin protein in N. meningitidis is PilE, which multimerises 
and forms anα-helical fibre with other “minor” pilins such as PilV and PilX (Cehovin et al. 
2010). The PilC proteins are other components of the Tfp machinery which are required for 
adhesion (Nassif et al. 1994).Pilin is essential for binding to epithelial cells and endothelial 
cells (Virji et al. 1991; Nassif et al. 1993), while pilus-mediated adhesion and filament 
retraction contribute to host-cell signaling and cytoskeletal rearrangements (Lambotin et al. 
2005). 
Studies conducted with N. gonorrhoeae, revealed that pilE undergoes antigenic 
variation (Koomey et al. 1987; Criss et al. 2005). Furthermore, neisserial pilins can undergo 
glycosylation, a post-translational modification which is subject to phase variation(Power et 
al. 2003). Glycosylation is not required for pilus formation, but can impair the aggregation of 
pili into bundles (Marceau and Nassif 1999). Tfp can also be modified with phosphocholine, 
PEA or phosphoglycerol, modifications that can cause the release of bacteria from 
aggregates,and could enhance dissemination in the host, favouring transmigration through 
epithelial cells (Chamot-Rooke et al. 2011).  
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1.6.4 Opa and Opc proteins 
Opa and Opc are neisserial OMPsthat facilitate the interaction of bacteria with 
epithelial and a variety of immune cells. Expression of Opa and Opc confers “opacity” to 
colonies of N. meningitidis when grown in vitro. This is noticeable in acapsulate strains, and 
reflects the contribution of Opc and Opa to cell adhesion (Virji et al. 1995). Opa and Opc 
bind at least two negatively charged molecules, HSPGs and sialic acids, but still exhibit 
receptor specificity (de Vries et al. 1998). Opa protein expression undergoes phase variation 
at the transcriptional level (Belland et al. 1997); therefore a bacterial population can include 
bacteria expressing none, one or multiple Opas (Jerse et al. 1994; Sadarangani et al. 
2011).Opa proteins have different structures and rearrangement of their domains results 
ininteractions with different carcinoembryonic antigen-related cell adhesion molecules 
(CEACAMs). CEACAMs are members of the immunoglobulin super-family and include several 
important receptors such as CEACAM1, CEACAM3 and CEA (Sadarangani et al. 2011).  
The majority of Opas target CEACAM1 on epithelial and phagocytic cells (Pantelic et 
al. 2004; Kuespert et al. 2011). Interestingly, expression of some CAECAMs is restricted to 
particular cells or tissues,and this may influence bacterial tropism. For instance, binding of 
Opa toCEACAM1 on neutrophils leads to phagocytosis and elimination of meningococci 
(Kuespert et al. 2011). Opc mediates adherence of non-piliated meningococci, probably 
through interaction with cell surface proteoglycans (de Vries et al. 1998). However, the 
precise proteoglycan receptors recognised by Opc have not been identified. Furthermore, 
Opc contributes to bacterial adhesion to endothelial cells by binding vitronectin in the 
extracellular matrix (ECM) (Virji et al. 1992b; Sa et al. 2010), which forms a molecular bridge 
with integrins on the cell surface.  
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1.6.5 Porins 
Porins are the most abundant OMPs in pathogenic Neisseria (Massari et al. 2003); in 
the gonococcus they are termed Por IA or IB, and in the meningococcus they are termed 
PorA (class 1 protein) and PorB (class 2 and 3 proteins) (Feavers and Maiden 1998; Nassif et 
al. 1999). There is structural and functional homology amongst neisserial porins and those 
of other Gram negative bacteria, with each porin monomer forming a ß-barrel fold and a 
pore for the passage of ions and/or solutes (Murakami et al. 1989). 
Neisserial porins translocate into the plasma membrane of eukaryotic cells, forming 
voltage gated ion channels and causing transient changes in membrane potential and 
interfering with cell signalling (Kozjak-Pavlovic et al. 2009). PorB is a non-selective porin that 
binds ATP molecules through a non-covalent interaction (Rudel et al. 1996). It allows 
passage of sugars and interacts directly with the host mitochondrial voltage-dependent 
anion channel (VDAC) (Minetti et al. 1997). Because both VDAC and the mithocondrial 
membrane potential control apoptosis, PorB might influence the initiation of apoptosis 
(Massari et al. 2010).  
An important contribution of porins to pathogenesis is their ability to modify immune 
responses;for example, TLR-2 binds PorB, probably even when TLR-2 is dimerised with TLR-1 
(Massari et al. 2006). However, the exact mechanism of interaction or the precise binding 
sites have not been elucidated, probably due to the variation in porin sequence, form and 
structure (Tanabe et al. 2010). 
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1.7 Host immunityagainstN. meningitidis 
Host defence against meningococci is determined by humoral and cellular responses 
belonging to both the innate and adaptive immune systems. It is well known that the 
complement system plays a crucial role in protection against invasive meningococcal 
disease, as complement deficiencies are associated with marked susceptibility to 
meningococcal disease (Densen 1991; Mathew and Overturf 2006). Furthermore, presence 
of bactericidal antibodies against N. meningitides can prevent the development of infection 
(Goldschneider et al. 1969a). However, the production of specific antibodies occurs only 
after one week of N. meningitidis colonisation, so that the initial defence is dependent 
mainly on innate immune responses (van Deuren et al. 2000). The sites where Neisseria are 
commonly found, such as the nasopharynx and the upper respiratory tract, may be deficient 
in the components of the complement system and are populated by immune cells such as 
resident phagocytes and T cells (Cooper and Moticka 1989; Fokkens and Scheeren 2000). 
Therefore, understanding the basis of the interactions between innate immune cells and the 
meningococcus is of particular importance and is the main subject of this thesis.   
Indeed, the immune cells which reside within epithelia contribute to the 
development of immunity and are the first line of defence against bacterial invasion. 
Immunosurveillance mechanisms are particularly active at this site and residentcells such as 
macrophages are responsible for a non-specific immune response initiated by initial contact 
with the meningococcus (Fokkens and Scheeren 2000). Bacterial pathogen associated 
molecular patterns (PAMPs) trigger a series of events leading to activation of resident 
macrophages and recruitment of neutrophils, monocytes, macrophages and dendritic 
cells(DCs) to the site of infection (Miller et al. 2005). In addition, meningococci provoke the 
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production of pro-inflammatory cytokines by immune cells, leading to stimulation of 
subsequent adaptive immune responses (Koedel 2009). Meningococci can evade some of 
these initial immune defences and reach the bloodstream where they are able to replicate 
and cause disease (Brandtzaeg and van Deuren 2002; Namork and Brandtzaeg 2002; 
Colicchio et al. 2009). 
 
1.7.1 Neutrophils in meningococcal disease 
Neutrophils are the most abundant population of circulating leukocytes and mediate 
the early phase of inflammatory responses (Peters et al. 2003). During N. meningitidis 
infection, there is considerable activation of neutrophils (Heyderman et al. 1999). This is 
dependent on the formation of platelet-neutrophil complexes which contain activated 
neutrophils and seem to be rapidly lost from the circulation during meningococcal disease 
(Peters et al. 2003). Furthermore, neutrophils are the predominant cell type in the CSF of 
patients with meningococcal meningitis (Arevalo et al. 1989).  
The importance of neutrophils in meningococcal disease has been demonstrated by 
depleting neutrophils in an infant rat model, a phenomenon that led to 100% mortality after 
challenge with N. meningitidis, even after vaccination (Peters et al. 2001). The principal 
mechanism neutrophils employ to destroy pathogens is through localised granule exocytosis 
and extracellular production of reactive oxygen species (ROS)(Criss and Seifert 2012). 
Neutrophils also produce extracellular traps which capture and inactivate bacteria that are 
distant from the neutrophil surface (Brinkmann et al. 2004; Young et al. 2011). The 
meningococcus has evolved mechanisms to overcome oxidative stress by encoding several 
proteins that detoxify ROS such as superoxide dismutase, catalase and cytocrome 
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cperoxidase (Seib et al. 2004). In addition, DNA repair systems have been recently shown to 
be responsible for correcting DNA damaged by oxidative stress (Nagorska et al. 2012). 
Moreover, resistance of N. meningitidis to phagocytosis has been widely described. It 
is well established that capsule prevents opsono-phagocytosis and killing by the 
complement system and is subsequently required for survival in the extracellular fluids 
(Read et al. 1996). However, other components of the N. meningitidis outer membrane can 
be involved in interaction with immune cells. Opa and Opc proteins are involved in the 
interaction of unencapsulated N. meningitidis with neutrophils. These adhesins contribute 
to non-opsonic phagocytosis of N. meningitidis by neutrophils (Estabrook et al. 1998), but 
the precise mechanisms have not been elucidated. Furthermore, sialylated LPS limits 
complement mediated phagocytosis and impairs resistance to immune mechanisms of the 
host (Kahler et al. 1998). Finally, it has been proposed that the acquisition of glutamate by 
meningococcus promotes survival of bacteria in association with neutrophils and enhances 
the ability of the bacterium to cause bloodstream disease. Specifically, glutamate is 
converted by bacteria into glutathione which regulates the redox potential of bacteria, thus 
protecting N. meningitidis from ROS production (Tala et al. 2011).  
 
1.7.2 Dendritic cells in meningococcal disease 
Dendritic cells have an important role in the activation and regulation of the human 
immune system; DCs can open tight junctions between adjacent epithelial cells and capture 
bacteria directly by recognising and phagocytosing pathogens (Salter and Watkins 2006). 
Contact with micro-organisms induces a maturation process that leads to down regulation 
of pathogen recognition receptors and up regulation of antigen presentation molecules 
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(Banchereau and Steinman 1998). During maturation, DCs migrate to secondary lymphoid 
tissues where they activate T cells. N. meningitidis is known to bind the DC-specific 
intracellular adhesion molecule 3 (ICAM-3) grabbing non integrin (DC-SIGN), a type II 
transmembrane receptor with a single extracellular C-type lectin domain. DC-SIGN binds 
mannose structures and fucose containing glycoconjugates (Feinberg et al. 2001; Appelmelk 
et al. 2003) and recognises truncated meningococcal LPS, mediates bacterial uptake, thus 
triggering a T-helper 1 (Th1) immune response(Steeghs et al. 2006). 
 
1.7.3 Monocytes and macrophagesin meningococcal disease 
Monocytes are a heterogeneous population of leukocytes present in the blood, 
spleen and bone marrow (Auffray et al. 2009; Swirski et al. 2009) that migrate to tissues 
during infection and inflammation (Geissmann et al. 2010; Shi and Pamer 2011). Monocytes 
have long been considered as a developmental intermediate between bone marrow 
precursors and tissue macrophages and DCs (Serbina et al. 2008). However, it is established 
now that DCs and tissue macrophages originate from distinct cells termed “inflammatory” 
monocytes (Geissmann et al. 2008). “Inflammatory” monocytes are characterised by specific 
effector functions and express a wide range of scavenger receptors (SRs) that recognise 
micro-organisms, toxic molecules and dying cells. Therefore monocytes provide a systemic 
reservoir of myeloid precursors of macrophages and DCs, and also link inflammation and 
adaptive immunity during infection.  
The interaction of N. meningitidis with monocytes has been studied (McNeil et al. 
1994). In particular, the importance of the expression of opacity proteins for bacterial 
adherence with monocytesand down regulation of the polysaccharide capsule has been 
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assessed (Unkmeir et al. 2002). Serogroup B N. meningitidis has been observed within 
monocytes during experimental infection of human nasopharyngeal mucosa (Read et al. 
1995). 
Monocytes are able to kill meningococci, but a smallpopulation of bacteria can be 
detected inside the cells several hours after challenge (Spinosa et al. 2007). This suggests 
that bacteria could be carried within the cells to distal tissues, although this hypothesis 
remains unproven.  
Macrophages are phagocytic cells present within the tissues and are responsible for 
the initiation and resolution of inflammation. Resident macrophages are sentinel cells 
detecting tissue damage and changes in local homeostasis following infection and injury 
(Liddiard et al. 2011). Their functions include clearance of apoptotic cells, tissue remodelling 
and repair, pathogen recognition and immune activation, and linking innate and adaptive 
immunity. Activated macrophages kill phagocytosed microbes through the action of lytic 
enzymes, ROS and nitric oxide (NO), and by releasing CAMPs into the extracellular space 
(Hancock 2001). 
Both monocytes and macrophages are “plastic” cells, as they assume diverse 
characteristics based on their stage of cellular differentiation, tissue distribution and 
response to endogenous and exogenous stimuli (Geissmann et al. 2010). Their “plasticity” 
can be induced by cytokines in vitro. For example, exposure of human and murine 
monocytes to granulocyte-stimulating factor (GM-CSF) and IL-4 induces differentiation into 
DCs, while exposure to macrophage colony-stimulating factor (M-CSF) induces 
differentiation into macrophages (Manzanero 2012). Furthermore, addition of LPS or IFN-γ 
and M-CSF to macrophages induces differentiation into M1-like macrophages (classically 
activated) whereas addition of IL-4 induces differentiation into M2-like macrophages 
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(alternatively activated). This type of differentiation is called polarisation and determines 
the functions. M1-like macrophages exhibit microbicidal properties and promote IL-12-
mediated,Th1 associated responses, while M2-like macrophages play a role in the resolution 
of inflammation and support Th2 response (Goerdt et al. 1999; Gordon 2003). Macrophages 
express several surface molecules which recognise micro-organisms, such as SRs which bind 
conserved motifs on pathogen surfaces (Pluddemann et al. 2009). In particular SR-A is 
involved in non-opsonic phagocytosis of the meningococcus by bone marrow derived 
macrophages (Peiser et al. 2002).  
Meningococci are found within macrophages during invasive infection (Read et al. 
1996), and uptake of N.meningitidis by these cells can occur without opsonisation.Once 
internalised by macrophages, meningococci are rapidly killed in phagolysosomal 
compartments whether or not they are encapsulated (Read et al. 1996). Similar to other 
Gram negative bacterial infections, cytokine release by macrophages is dependent on the 
presence of LPS and TLR-4 (Zughaier 2011). 
 
1.8 Immune recognition 
The innate immune system has evolved to specifically recognise and eliminate 
potentially dangerous micro-organisms. Cells responsible for this response sense PAMPs 
through specific receptors called pattern recognition receptors (PRRs) to elicit immune cell 
signalling (Fig. 1.4). 
Cell surface TLRs are PRRs that recognise PAMPs on the bacterial surface, such as the 
LPS of Gram negative bacteria (TLR-4), lipoteichoic acid of Gram positive bacteria, bacterial 
lipoproteins (TLR-1/TLR-2 and TLR-2/TLR-6), and flagellin (TLR-5). Endosomal TLRs mainly 
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detect nucleic acids, such as double stranded RNA (dsRNA) (TLR-3), single stranded RNA 
(ssRNA) (TLR-7) and dsDNA (TLR-9). Activation of TLRs leads to specific signalling cascades 
resulting in antimicrobial and inflammatory responses that are dependent on the receptors 
activated (Akira et al. 2001).  
Transmembrane PRRs include TLRs and C-type lectin receptors (CLRs). CLRs are 
expressed by immune cells and can distinguish between different pathogens,consequently 
eliciting signalling pathways to initiate appropriate immune responses. Examples of CLRs are 
DC-SIGN, MBL (which is specific for terminal GalNAc structures), and Dectin-1 (which 
recognises ß-glucans and mannans in fungal cell walls) (Saijo and Iwakura 2011). 
PRRs can also recognise endogenous ligands termed damage-associated molecular 
patterns (DAMPs), which are released by host cells upon tissue damage and acute 
inflammation or tumour growth (Matzinger 2002; Kono and Rock 2008). DAMPs have gained 
major attention for anti-cancer therapy, as cancer cells which die following UV treatment 
release molecules which improve immune responses against the cancer cells (Garg et al. 
2010).  
The list of DAMPs includes heat shock proteins, high mobility group protein-1 
(HMGB-1), IL-1α, defensins and annexins (Rubartelli and Lotze 2007). In addition, as glycan 
structures are present on host and bacterial cells, these molecules may play a role in the 
communication between microbes and the host. Lectins, which act as receptors that can be 
secreted or expressed on the surface of immune cells, include sialic acid-binding 
immunoglobulin domains (siglecs) and galectins. Siglecs are surface receptors which bind 
sialic acid containing glycans (Dam and Brewer 2010); galectins are described in the next 
section. 
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1.9 Galectins in innate immunity 
Galectins are a family of animal lectins that recognise β-galactoside structures 
(Barondes et al. 1994), share sequence similarity in a carbohydrate recognition domain 
(CRD) of approximately 130 amino-acids and lack a signal peptide. Galectins can be exported 
by an atypical secretory pathway and function mainly extracellularly where they recognise 
glycans and mediate inter-cellular communication (Sato et al. 2009). 
To date, 15 galectins have been identified in mammals and these are divided into two 
subtypes; proto-type galectins have a single CRD (galectin-1, -2, -3, -5, -7,-10,-11, -13, -14 
and 15) while tandem-repeat galectins have two CRDs joined by a short linker (galectin -4, -
6, -8, -9 and -12) ((Liu and Hsu 2007) and Fig. 1.5). Among the single CRD type galectins, 
galectin-3 is unique as it is a chimeric galectin which also contains an N-terminal domain 
(ND) of approximately 120 amino acids that allows the formation of pentamers (Ahmad et 
al. 2004a).  
Most galectins are soluble proteins, although some galectins including galectin-3 
have been proposed topossess a transmembrane domain and can be expressed as a soluble 
protein or a transmembrane protein (Gorski et al. 2002). The minimal saccharide unit 
recognised by galectins is a galactose residue linked to an adjacent monosaccharide in the ß-
configuration (i.e. aß galactoside). In particular, glycans that contain polylactosamine chains 
((Galß1, 4GlcNAc)n) such as laminin, fibronectin or lysosome associated membrane proteins 
are endogenous galectin ligands (Inohara and Raz 1994; Ochieng et al. 1998b; Barboni et al. 
1999). 
Although all galectins recognise ß-galactosides, specific glycan structures are 
necessary for efficient binding, and the affinity of each galectin for its ligand is dependent 
on substitutions of the ß-galactoside (Rapoport et al. 2010). In addition, differences in the 
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biological effect of galectin-1 and galectin-3 result from diversity in the tertiary structure of 
the protein rather than ligand binding properties (Seetharaman et al. 1998). 
The roles of galectins in the development and regulation of innate and adaptive 
immune homeostasis have been recently reviewed (Rabinovich and Toscano 2009).Galectins 
are synthesised and accumulate in the cytoplasm of immune cells, as well as fibroblasts, 
keratinocytes, endothelial cells and epithelial cells (Cerliani et al. 2011). Once host cells are 
damaged following pathogen invasion, galectins are released and function as lectins. 
However, galectins are also actively secreted during cell differentiation or activation, and 
can trigger cell signalling, mediate cell-cell interaction and induce migration of monocytes, 
macrophages and endothelial cells (Dumic et al. 2006). 
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Figure 1.5Schematic structure of galectins from different groups. 
Proto-type galectins are formed by two identical CRD (galectin-1, -2, -3, -5, -7,-10,-11, -13, -
14 and 15), the chimera-type galectins by a CRD connected to an ND (galectin-3) and the 
tandem-repeat galectins have two dinstinct CRDs joined by a short linker (galectin -4, -6, -8, 
-9 and -12). 
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1.10 Galectin-3 
Galectin-3 is the sole chimera-type galectin as it contains an ND consisting of multiple 
repeats of a sequence rich in proline (Pro), glycine (Gly) and tyrosine (Tyr) residues (Fig. 1.5 
and 1.6). Upon ligand binding, the conformation of galectin-3 changes in a concentration-
dependent manner, and galectin-3 oligomerises through its N-terminal regulatory domain; 
this oligomerisation results in the formation of a galectin-3 complex with multiple CRDs. 
Multimerisation is reversible and can occur following cleavage by certain proteases 
including metalloproteinases (MMPs) and bacterial collagenase IV. Truncated galectin-3 can 
still bind its ligands but has limited functions (Kopitz et al. 2001).  
Galectin-3 can also be phosphorylated (Mazurek et al. 2000) and this form is found in 
the cytosolic and nuclear fractions of cultured fibroblasts (Tsay et al. 1999) and epithelial 
cells (Mazurek et al. 2005). Phosphorylation of the N-terminal regulatory domain 
significantly reduces its affinity for ligands, possibly by affecting the ability of the protein to 
multimerise (Mazurek et al. 2000). 
Galectin-3 has marked preference for polylactosamine structures located at 
accessible sites on glycoconjugates (Togayachi et al. 2007). The affinity of the interaction 
increases in proportion to the number of polylactosamine units present on the glycan chain. 
Galectin-3 was initially identified as a cell surface component of macrophages, even 
though it is not a conventional membrane protein (Bornstein and Sage 2002). Like the other 
galectins, galectin-3 does not contain obvious secretion sequences but it can be released 
and has different functions, depending on its localisation (Liu and Hsu 2007).  
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1.10.1 Intracellular functions of galectin-3 
Intracellular galectin-3 is located in the nucleus and the cytoplasm, with the relative 
distribution influenced by the cell type and specific experimental conditions (Haudek et al. 
2010).The cytoplasmic fraction contains only phosphorylated galectin-3, while the nuclear 
fraction has the phosphorylated and non-phosphorylated protein (Tsay et al. 1999). 
Galectin-3 has important roles in the regulation of cell cycle and apoptosis. 
Intracellular galectin-3 can inhibit apoptosis (Liu and Hsu 2007) which is likely to be 
dependent onits phosphorylation (Yoshii et al. 2002). Initially, galectin-3 phosphorylation 
was shown to occur on residues Ser6 and Ser12; more recently, phosphorylation has been 
shown to occur on residues Tyr79, Tyr107 and Tyr118of the collagen-like sequence rich in Gly, 
Pro, Tyr and glutamine (Gln) residues through the action of c-Abl and Arg (c-Abl related 
gene) kinases ((Balan et al. 2010; Balan et al. 2012) and Fig. 1.6). 
Galectin-3 and Bcl-2 proteins share high sequence identity and are rich in Pro, Gly 
and alanine (Ala, A) in theirN-terminal regions. Moreover, they both contain asequence of 
asparagine (Asn, N), tryptophan (Trp, W), Gly (G) and arginine (Arg, R) in their CRD, a quartet 
conserved in the Bcl-2 family proteinsthat is critical for its anti-apoptotic activity (Kim et al. 
1999; Yang and Liu 2003). Galectin-3 directly interacts with Bcl-2 in the cytoplasm, 
mimicking the ability of the Bcl-2 family members to form heterodimers (Haudek et al. 
2010). Moreover, intracellular galectin-3 also regulates cell cycle and differentiation. Cells 
overexpressing galectin-3 undergo G1 arrest without detectable cell death (Kim et al. 1999). 
The NWGR motif is essential for regulation of cell cycle activity, as substitution of the Gly 
with Ala leads to loss of this function (Akahani et al. 1997). 
Galectin-3 can bind nucling, another pro-apoptotic protein in the cytoplasm, and 
synexin, a calcium- and phospholipid-binding protein (Haudek et al. 2010). Another ligand 
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for galectin-3 in the cytoplasm is the transcription factor Suppressor of fused (Sufu), which 
serves as a shuttle between the cytoplasm and the nucleus (Paces-Fessy et al. 2004). 
Therefore, galectin-3 has been proposed to play a role in the nuclear versus cytoplasmic 
distribution of Sufu, thus affecting its trascriptional activity (Haudek et al. 2010). 
  
43 
 
 
Figure 1.6. Protein sequence of galectin-3 and structure of the CRD. 
(A) Galectin-3 amino acid sequence showing the ND (black) and the CRD (red). The repeats 
of Pro-Gly-Ala-Tyr-Pro-Gly (green) in the ND, Ser5 and Ser11 phosphorylation sites (blue) and 
the Met127 cleavage site (in bold) are indicated. (B) Representation of the CRD of galectin-3 
complexed with LacNAc (dark blue and yellow). β-strands are shown in light blue and yellow 
(Protein Data Bank structure, www.rcsb.org/pdb/explore.do?structureId=1KJL).  
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1.10.2 Extracellular functions of galectin-3 
Release of galectin-3 can be due to cell necrosis (passive release) or through an 
active process from live cells (active release) (Hughes 1999). It has been suggested that the 
release of galectin-3 is tightly regulated by cell differentiation (van Stijn et al. 
2009).Galectin-3 is up-regulated during inflammation; for example, high concentrations of 
the protein are found in bronchoalveolar lavage fluids (> 50 µg/ml) following Streptococcus 
penumoniae infection (Henderson and Sethi 2009). Moreover, this lectin has been used as a 
marker of inflammation for microglia (Venkatesan et al. 2010), and contributes to brain 
damage in pneumococcal meningitis, where immune cells are responsible for galectin-3 
expression (Bellac et al. 2007). 
Once galectin-3 is secreted it binds to ß-galactoside containing glycoconjugates on 
cell surfaces and undergoes oligomerisation.One of the important mechanisms by which 
galectins regulate their functions is through their ability to create galectin-glycoprotein 
complexes. As galectin-3 is multivalent, it can cross link specific ligands on the cell surface, 
induce clustering on the surface (called lattice) and trigger responses that can lead to 
cytokine production (Rabinovich et al. 2002). 
Extracellular galectin-3 binds to ECM proteins such as fibronectin, laminin, collagen 
IV, elastin, hensin, tanascin-C and -R (Dumic et al. 2006). Furthermore it binds to certain 
integrins present on the surface of macrophages, such as CD11b (α subunit of αMβ1 
integrin, CD11b/18, Mac1 antigen) (Dong and Hughes 1997), and the α3 β1 integrin on 
epithelial cells, triggering signalling that leads to theformation of lamellipodia (Saravanan et 
al. 2009). Moreover, galectin-3 associates with the heavy chain of CD98, a membrane 
glycoprotein present on monocytes/macrophages and activated T cells, and mediates CD98 
dimerisation (Dong and Hughes 1996). CD98 is required for activation of an alternative 
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macrophage phenotype once bound to galectin-3, suggesting that galectin-3 is involved in 
the resolution of inflammation (MacKinnon et al. 2008). Galectin-3 also binds 
aminopeptidase N (CD13), a metalloproteinase expressed by monocytes. Galectin-3 binding 
to CD13 has been suggested to influence homotypic aggregation, a process that leads to 
cellular activation and maturation in tumour cell invasion and metastasis (Mina-Osorio et al. 
2007). In contrast to intracellular galectin-3, extracellular galectin-3 can induce apoptosis of 
T cells, through caspase activation, leading to an immunosuppressive effect (Stillman et al. 
2006). 
Extracellular galectin-3 is also involved in inflammatory responses, contributing to 
autoimmune diseases and responses to infection (Dhirapong et al. 2009). Galectin-3 
knockout murine macrophages are more sensitive to apoptotic stimuli and exhibit reduced 
pro-inflammatory responses in terms of leukocyte recruitment (Nieminen et al. 2008). 
Moreover, mice lacking galectin-3 excessively produce inflammatory cytokines and NO and 
are more susceptible to LPS induced shock, but at the same time 
impairSalmonellareplication. These data suggested that galectin-3 protect against endotoxic 
shock but might be detrimental by favouring early Salmonella invasion (Li et al. 2008). 
Galectins are potential opsonins, as they can cross-link ligands on cells or apoptotic 
bodies to cells. For example, galectin-3 can bind apoptotic neutrophils and facilitate their 
uptake by macrophages (Karlsson et al. 2009). In addition, galectin-3 is able to activate the 
nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase of human neutrophils 
(Yamaoka et al. 1995; Karlsson et al. 1998). 
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1.11 Galectin-3 binding to micro-organisms 
Although galectin-3 was initially thought to bind only endogenous glycans, it is 
becoming increasingly recognised that it also binds glycans on pathogenic micro-organisms, 
and mediates recognition and effector functions in innate responses to infection (Sato and 
Nieminen 2004; Nieminen et al. 2008). Several pathogens express glycoconjugates that 
contain ß-galactosides similar to those present on host cells. For example, N. meningitidis, 
N. gonorrhoeae and H. Influenzae can express polylactosamine (Gal ß1-4GlcNAc ß1-3Gal ß1-
4Glc) in their LPS. Therefore galectin-3 on macrophages and epithelial cells might recognise 
these glycans on pathogens. Differences in the LPS structures of Gram negative bacteria 
affect interactions with galectin-3 (Vasta 2009).Variation in LPS is most marked in the O-
antigen, a polysaccharide chain that extends from core saccharides (Wang et al. 2010). 
Galectin-3 binds LPS from Klebsiella pneumoniae (which has a β-galactoside-containing O-
antigen) through its CRD (Mey et al. 1996). In contrast, LPS from Salmonella minnesota R7 
(Rd mutant), which is devoid of β-galactosides, is recognised by the ND of galectin-3 binding 
to the lipidA/inner core portion of LPS (Mey et al. 1996). Furthermore, galectin-3 binds to 
the gonococcus via LPS, with highest affinity for glycoforms terminating in LacNAc (John et 
al. 2002).  
Galectin-3 can bind glycans expressed by several parasites, including Leishmania 
major, Schistosoma mansoni and Trypanosoma cruzi (Pelletier and Sato 2002; van den Berg 
et al. 2004; Silva-Monteiro et al. 2007), and fungi such as Candida albicans (Fradin et al. 
2000; Kohatsu et al. 2006). Importantly, galectin-3 recognition of Candida results in 
significant reduction of fungal viability (Fradin et al. 2000). 
In addition, galectin-3/pathogen interactions may mediate pathogen adhesion to 
cells and therefore facilitate infection. Consistent with this, galectin-3 binding to the O-
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antigen of Helicobacter pylori promotes attachment of bacteria to cells (Fowler et al. 
2006b). Moreover, a recent study showed that galectin-3 enhances neutrophil activation by 
increasing the ability of LPS to bind neutrophils (Fermino et al. 2011). 
In general galectin-3 may provide direct innate immune functions during infection, as 
demonstrated by its protective role inpneumococcal pneumonia, where it augments 
neutrophil activity (Farnworth et al. 2008). Furthermore, galectin-3 can enhance PMN 
recruitment to S. pneumoniaein vivo and act as a soluble adhesion molecule for neutrophils 
on endothelial cells (Nieminen et al. 2008). 
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1.12 Other galectins examined in the study 
1.12.1 Galectin-1 
Galectin-1 is a proto-type galectin, widely distributed in different tissues including 
epithelial cells, endothelial cells, trophoblasts, activated T cells, macrophages, activated B 
cells and DCs (Camby et al. 2006). In addition, its expression has been shown to be 
modulated in several pathological conditions, such as cancer, infection or autoimmune 
disease, and it has been proposed to control leukocyte trafficking, immune tolerance and 
homeostasis (Cooper et al. 2010).  
In general, galectin-1 has an anti-inflammatory effect by impairing signalling events 
that lead to leukocyte infiltration, migration and recruitment (Kiss et al. 2007). It also has 
pro- or anti- apoptotic effects on T cells depending on their developmental stage and 
activation, and the local cytokine environment (Pace et al. 1999). 
Galectin-1 promotes HIV infection either by enhancing binding of the virus to cells, or 
acting as a soluble receptor to facilitate uptake by macrophages. Virus attachment and host 
cell fusion occurs by binding N-linked oligosaccharides on the virion envelope (St-Pierre et 
al. 2011). 
 
1.12.2 Galectin-4 
Galectin-4 is a tandem-repeat galectin first identified in the luminal epithelium of the 
intestinal tract of mammals (Wasano and Hirakawa 1995; Wooters et al. 2005; Paclik et al. 
2008), and in the rabbit bladder epithelium (Bhavanandan et al. 2001). However, galectin-4 
expression is also detected in the lungs, testes, breast, liver and placenta by reverse 
transcriptase polymerase chain reaction (RT-PCR) (Markova et al. 2006). It is mainly present 
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intracellularly and is a tumor suppressor which inhibits cell proliferation by down-regulating 
Wnt signalling (Satelli et al. 2011). The CRD of galectin-4 has also been implicated in 
inflammatory bowel disease (Paclik et al. 2008), and linked to cancer progression (Satelli et 
al. 2011). Human galectin-4 consists of two non-identical CRDs of 133 aminoacids each 
connected by a linker peptide of 17 aminoacids (Huflejt and Leffler 2004). The carbohydrate 
binding specificities of each CRD are distinct and exhibit preference for different ligands 
(Wasano and Hirakawa 1999; Wu et al. 2002). The two domains share40% amino acid 
identity, whilethe proline and glycine rich linker is sensitive to proteases (Huflejt and Leffler 
2004).   
 
1.12.3 Galectin-7 
Galectin-7 is a proto-type galectin that can dimerise in solution (Morris et al. 2004). It 
contributes to epithelial cell migration and the establishment of epithelial layers, and is a 
potential marker of keratinocyte differentiation (Madsen et al. 1995; Timmons et al. 1999; 
Cao et al. 2002; Cao et al. 2003).  
More recently, galectin-7 has been shown to have a role in apoptosis;it is over-
expressed in colorectal cancer cells undergoing p53-dependent apoptosis, and has been 
proposed to aid the elimination of neoplastic cells (Demers et al. 2010).  
Galectin-7, like the other galectins, binds a large range of ligands. Thermodynamic 
studies demonstrated that galectin-7 possesses weaker affinities for carbohydrates with 
LacNAc epitopes compared with galectin-1 (Brewer 2004). Galectin-7 specific ligands in vivo 
have not been identified yet, but clear differences in its carbohydrate binding specificity 
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have been observed; galectin-7 binds non-reducing terminal and internal LacNAc residues of 
poly-N-lactosamine chains often found on glycoprotein receptors (Morris et al. 2004). 
 
1.12.4 Galectin-8 
Galectin-8 is a tandem-repeat galectin of 34 kDa, composed of two CRDs connected 
by a linker peptide. The N- and C- terminal domains share approximately 35% amino acid 
identity and contain sequence motifs that are conserved among CRDs from most galectins 
(Dumic et al. 2006). Galectin-8 can be secreted or present in the cytoplasm particularly in 
association with Golgi or trans-Golgi membranes and mitochondria (Zick et al. 2004). 
Galectin-8 is expressed in many tissues including the liver, lung, spleen and kidneys, while 
low levels of the protein are detected in the colon, intestine, and thymus (Bidon et al. 2001).  
The physiological role of galectin-8 is not completlely understood, but multiple 
functions, such as cell adhesion, growth and differentiation, have been proposed. For 
example, it has an inhibitory effect on cell adhesion by binding several integrins on human 
cells (Hadari et al. 2000), and mediates adhesion of peripheral blood neutrophils to the 
endothelium (Nishi et al. 2003).  
 
1.12.5 Galectin-9 
Galectin-9 is another member of the tandem-repeat galectins, and has been shown 
to induce apoptosis in monocytic and myeloid cell lines through carbohydrate dependent 
mechanisms (Kuroda et al. 2010). Galectin-9 has been found in both immature and mature 
DCs and induces transcription of pro-inflammatory cytokines such as IL-1α, IL-1β and IFN-γ 
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(Dai et al. 2005). DC maturation induced by galectin-9 probably depends on signalling by p38 
and is only partially inhibited by lactose (Dai et al. 2005).  
In vivo, proteolytic cleavage within the linker region of galectin-9 by elastase matrix 
metalloproteinase-3 as well as insertional mutationscan generate two independent 
functional CRDs (Lahm et al. 2000; Nishi et al. 2005). Consistent with this, studies on the two 
separate domains have shown that they have distinct properties.The N-terminal CRD of 
human galectin-9 exhibits affinity for poly-N-acetyl-lactosamine (poly-LacNac) and 
selectivity for N glycans present on cells without 2,3 sialylation (Solis et al. 2010). In 
contrast, the the C-terminal CRD has high affinity for single LacNAc molecules and α-2,3-
sialylated oligosaccharides (Yoshida et al. 2010). The N- and C- terminal CRDs of galectin-9 
also contribute differently to its multiple functions. The N-terminal CRD is a potent activator 
of innate immune cells, while the C-terminal CRD is mainly involved in adaptive immunity by 
inducing T-cell death (Li et al. 2011). 
Galectin-9 also binds the T cell immunoglobulin and mucin domain containing 
molecule 3 (TIM-3) which is expressed on immune cells and promotes tissue inflammation 
(Jayaraman et al. 2010). 
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1.13 Aims of the thesis 
This project has three main objectives. 
Galectins have multiple roles in fundamental biological processes such as cell growth 
and differentiation,and modulate inflammation and immune responses to parasitic and 
bacterial infections. They are capable of recognizing host cell ligands as well as structures 
present on the surface of micro-organisms. N. meningitidis infection is characterised by a 
marked inflammatory response at the mucosal surface and in the systemic circulation. As 
galectins are expressed and produced by immune cells, and these cells are encountered by 
N. meningitidis at mucosal sites or in the bloodstream during bacterial colonisation and 
disease, the first goal of this project was to investigate the distribution of galectins in tissues 
and their expression by cells during meningococcal infection. 
Most of the literature about galectins focuses on the chimera-type galectin-3, which 
is secreted by or expressed on the surface of monocytes, macrophages and epithelial cells, 
and involved in many immune processes. Galectin-3 has been shown to bind the LPS of 
several bacteria including E. coli, K. pneumoniae and N. gonorrhoeae. Meningococcal and 
gonococcal LPS have similar structures which differ only in certain substitutions of the 
oligosaccharide portion. Therefore, the second goal of my thesis was to investigate whether 
galectin-3 would bind N. meningitidis. 
Current knowledge on the interactions of galectins with bacteria is limited to the 
function of the intracellular proteins and little is known about the roles of extracellular 
proteins during infection. Moreover, the functionof galectin-3 in meningococcal disease has 
never been examined. Galectin-3 is present in the intracellular environment but also in the 
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extracellular space, and it ispossible that N. meningitidis, as an extracellular bacterium, 
encounters galectin-3 during invasion of the host. Indeed, bacteria are exposed to epithelial 
cells at the site of colonisation, resident macrophages in the submucosa, and circulating 
monocytes, recruited macrophages and PMNs in the systemic circulation. Therefore, taking 
into account that galectin-3 is produced by these cells, the final aim of my project was to 
investigate whether galectin-3had an influence on bacterial interactions with host cells. 
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CHAPTER 2: Materials and Methods 
 
2.1 Bacterial strains and growth conditions 
N. meningitidis was grown on Brain Heart Infusion (BHI) agar (1.5% wt/vol, 
Oxoid) supplemented with 50 ml of defibrinated horse blood (previously autoclaved 
with 1 liter BHI broth) at 37°C in the presence of 5% CO2 for 16-18 hours. Solid media 
was inoculated from frozen stocks of bacteria stored at -80°Cin media with 15% 
glycerol. Bacteria were enumerated in a suspension of phosphate buffer saline (PBS) 
by measuring the optical density (O.D.) at 260 nm (A260). MC58 is a serogroup B 
isolate of N. meningitidis. The strains used in this study are described in Table 2.1.  
 
2.2 Cell culture 
THP-1 and Detroit 562 human cells line were purchased from American Type 
Culture Collection (ATCC). THP-1 cells are a human acute monocytic leukemia cell line 
established from the peripheral blood of a 1-year-old boy with acute monocytic 
leukemia (Tsuchiya et al. 1980). THP-1 cells were grown in RPMI 1640 medium 
(Gibco, Invitrogen) with 2 mM glutamine, supplemented with 10% fetal calf serum 
(FCS), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM 
sodium pyruvate, 14 mM D-glucose, 0.05 mM beta-mercaptoethanol. THP-1 
monocytic cells (1 x 106) were differentiated into macrophages in 24 well-plates 
containing 1 ml RPMI 1640 medium with 100 ng/ml 12-phorbol 13-myristate acetate 
(PMA) for 72 hours. 
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Detroit 562 is a human pharyngeal cell line which was maintained in Dulbecco’s 
modified Eagle’s medium (Gibco, Invitrogen) supplemented with 10% FCS, 2 mM 
GlutamaxTM (Invitrogen), 1 mM sodium pyruvate and lactalbumin hydrolysate (0.1%). Cells 
were cultured to a density of 1-5 x 105cells/ml and maintained at 37°C with 5% CO2.  
 
2.3 Galectins and antibodies 
The lectins used in this work were either purchased as recombinant proteins from 
R&D Systems (human galectin-3), or purified label free or biotinylated after production by 
affinity chromatography on lactosylated Sepharose 4B and kindly provided by Professor 
Hans-Joachim Gabius, University of Munich (Table 2).LPS was removed by a further 
chromatographic step as previously described (Sarter et al. 2009). Purity was ascertained by 
one- and two-dimensional gel electrophoreses and mass spectrometry, which was also 
performed after proteolytic truncation with collagenase D at the Tyr106/Ile107 and 
Glu229/Ile230peptide bonds of galectin-3; biotinylation was carried out under activity 
preserving conditionsas described (Kubler et al. 2008). Activity controls were run by solid-
phase and cell assays (Andre et al. 2007). Polyclonal antibodies against full length galectin-1, 
galectin-3 and galectin-4 were provided by Professor Gabius and were made and checked 
for specificity and absence of cross-reactivity to other galectins as previously described 
(Kaltner et al. 2002; Lohr et al. 2007; Lohr et al. 2008). Rabbit poly-clonal anti-human 
galectin-3 antibody was purchased from Santa Cruz Biotechnology. 
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Table 2.1 Meningococcal strains used in this study. 
Strain Description Immunotype References 
MC58 Serogroup B clinical isolate L3,7,9 (Plested et al. 1999; 
Tettelin et al. 2000) 
F8238 Serogroup A clinical isolate L10 (Maslanka et al. 1997) 
Z2491 Serogroup A clinical isolate L9 (Parkhill et al. 2000) 
H44/76 Serogroup B clinical isolate L3 (Holten 1979; Plested et 
al. 1999) 
8013 Serogroup C clinical isolate L3,7,9 (Rusniok et al. 2009) 
FAM18 Serogroup C clinical isolate L3,7,9 (Bentley et al. 2007) 
MC58∆siaC Insertionally inactivated siaC - (Exley et al. 2005) 
MC58∆siaD Insertionally inactivated siaD - (Exley et al. 2005) 
MC58∆lst Insertionally inactivated lst - (Exley et al. 2005) 
MC58∆lgtA Truncated LPS mutant - (Jennings et al. 1995b) 
MC58∆lgtB Truncated LPS mutant - (Jennings et al. 1995b) 
MC58∆galE Truncated LPS mutant - (Jennings et al. 1995b) 
MC58∆lsi-1 Truncated LPS mutant - (Jennings et al. 1995b) 
MC58∆icsB Truncated LPS mutant - (van der Ley et al. 1997) 
 
  
57 
 
Table 2.2 Galectins usedin this study. 
Compound Form Species 
Gal-3 full length Label free, Santa cruz 
Biotechnology 
Human 
Gal-3 CRD Purified label free Human 
Phosphorylated gal-3 Purified label free and modified 
with CK-1 
Human 
Gal-3 full length Purified label free and 
biotinylated 
Mouse 
Gal-3 CRD Purified label free and 
biotinylated 
Mouse 
Gal-3 full length Purified label free Chicken 
Gal-3 CRD Purified label free Chicken 
Gal-1 Purified label free Human 
Gal-1 treated with DTT (Gal-1 
DTT) 
Purified label free Human 
Gal-1 treated with IAA (Gal-1 
IAA) 
Purified label free Human 
Gal-1 C2S Purified label free and mutated 
at the dimer interface 
Human 
Gal-4 Purified label free Human 
Gal-7 Purified label free and 
biotinylated 
Human 
Gal-8 full length Purified label free Human 
Gal-8 ND Purified label free Human 
Gal-9 Purified label free Human 
Gal-9 ND Purified label free Human 
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2.4 Challenge of mice with live Neisseria meningitidis 
Groups of ten 6-week old female BALB/c mice (Harlan) were housed under 
pathogen-free conditions, acclimatised for one week and randomly distributed in two 
groups. Animals were challenged by intraperitoneal injection of N. meningitidis 
MC58. Bacteria were grown overnight on BHI plates and then harvested into PBS. 
The number of colony forming unit (CFU) was estimated by measuring the A260 of a 
lysate of the suspension in 200 mM sodium hydroxide (NaOH) and 1% (w/v) SDS 
solution (P2 lysis buffer Qiagen), and the number of viable bacteria was confirmed by 
plating to solid media. Each animal in the challenge group received 1x106 CFU of 
MC58 in 0.5 ml of BHI medium containing 0.5% (vol/vol) iron dextran (Sigma, Poole, 
United Kingdom). Control groups consisted of mice given BHI medium with iron 
dextran alone (i.e.uninfected). After 24 or 48 hrs, animals were sacrificed and organs 
collected, fixed in 10% formalin for one week and embedded in paraffin. Sections of 
five micrometer thickness were cut from each block for analysis. All animal 
experiments were carried out under protocols reviewed and approved by the Home 
Office, United Kingdom. Challenge of mice was performed by Dr. Yanwen Li (Imperial 
College). 
 
2.5 Immunohistochemistry 
The presence of galectin-1, -3, and -4 was assessed in different organs from 
mice challenged with N. meningitidis strain MC58 or uninfected animals, and the 
presence of galectin-3 was assessed in spleen tissue sections from patients with 
systemic meningococcal infection and uninfected patients. Tissues were obtained 
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during a study performed in 1991-1992 and kindly supplied by Professor S. Lucas, St. 
Thomas Hosptital (Lucas et al. 1993). Paraffin-embedded sections were deparaffinised in 
xylene, and rehydrated in serially diluted ethanol (100%, 95%, 75%, 50% and 0%). Following 
washes with distilled water for 5 min, sections were incubated with 3% methanol for 10 min 
to quench endogenous peroxidase. For antigen retrieval, specimens were boiled in 10 mM 
sodium citrate buffer under full vapour pressure for 2 min, and washed in distilled water 
and in PBS/0.1% Tween-20. Following incubation with 150 μl of protein block (Dako) for 5 
min, samples were incubated overnight at 4°C with 200 μl of rabbit polyclonal anti-galectin-
3 antibody (2 μg/ml) or 200 μl of a 1/500 dilution of mouse polyclonal antibody against N. 
meningitidis(Fitzgerald Industries International). The following day, sections were washed 
with PBS/0.1% Tween-20 and incubated with 100 μl of goat anti-rabbit or mouse antibody 
conjugated with horseradish peroxidase (HRP, Dako) or alkaline phosphatase (AP, Dako) for 
30 min. After washing with PBS/0.1% Tween-20, galectins in the tissues were visualised by 
incubation in diaminobenzidine (DAB) for HRP or permanent red forAP. Finally, tissue 
sections were counterstained with Mayer’s hematoxylin, mounted and analysed with a light 
microscope. Immunohistochemical analysis was performed with the help of Dr. Yanwen Li 
(Imperial College). 
 
 
 
 
60 
 
2.6 Biochemical procedures 
2.6.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
For whole cell lysates, bacteria were grown for 16 hours on BHI agar, 
harvested and resuspended in 400 μl of PBS for quantification (A260). 1x10
9 bacteria 
were re-suspended in 50 µl of dH2O and combined with an equal volume of 2x SDS 
sample buffer (50 mM Tris-HCl, 2% SDS, 100 μM ß-mercaptoethanol, 10% glycerol, 
0.1% bromophenol blue). Prior to loading, samples were boiled for 10 minutes, 
centrifuged briefly and 10-20 μl analysed by SDS-PAGE. For eukaryotic cells, aliquots 
of 1x106 adherent cells were removed with trypsin and re-suspended in dH2O. Cell 
suspensions were then centrifuged (1500 rpm for 8 minutes) and suspended in 25 μl 
of dH2O combined with an equal volume of SDS-PAGE sample buffer. SDS-PAGE 
analysis of proteins was performed according to the method described by Sambrook 
(Sambrook and Gething 1989) and 12% polyacrylamide gels prepared according to 
the recipes shown in Table 2.3. Protein samples were separated under reducing 
conditions by 12% SDS-PAGE at 120 V for 2 hours and protein standard Precision Plus 
All Blue markers (BioRad) was used as a marker (size from 10 kDa to 250 kDa). 
Table 2.3 Polyacrylamide gel recipes for 10 ml solutions. 
Separating Gel  Stacking gel  
ddH20 1.32 ml ddH20 
1.21 
ml 
1.5 M Tris pH 8.8 1 ml 1.5 M Tris pH 6.8 0.5 ml 
10% SDS 40 μl 10% SDS 20 μl 
40% Acrylamide 1.6 ml 40% Acrylamide 
0.25 
ml 
10% ammonium 
persulphate 
40 μl 10% ammonium persulphate 20 μl 
TEMED 1.6 μl TEMED 2 μl 
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2.6.2 Preparation of lipopolysaccharides from N. meningitidis 
N. meningitidis strains were harvested after overnight growth on BHI agar plates at 
37°C in the presence of 5% CO2 and re-suspended in PBS. The number of bacteria was 
estimated by measuring the A260 of an aliquot of the bacterial suspension lysed in P2 lysis 
buffer (1% SDS, 0.1% sodium hydroxide) using a UVVIS spectrophotometer (Schimadzu UK). 
A total of 1x109CFU were centrifuged (13000 rpm for 5 minutes) and pellets were re-
suspended in 50 µl of LPS buffer (3% SDS, 3%beta-mercaptoethanol, 5 mM dithiothreitol 
(DTT), 23% glycerol, 30 mM Tris pH 8, 0.05% bromophenol blue), then boiled for 10 minutes 
and incubated overnight at 37° following addition of 1 mg/ml of proteinase K solution 
(Qiagen).  
 
2.6.3 Electrophoresis of lipopolysaccharide 
LPS samples were analysed by separation in SDS-sulphate polyacrylamide gels 
formed by a separating gel (3M Tris, 0.3% SDS, pH 8.45, 20 mM Urea, 40% acrylamide, 10%, 
tetramethylethylenediamine, TEMED) and a stacking gel (0.5 M Tris pH 6.8, 40% Acrylamide 
bis, 10% SDS, 10% ammonium persulphate, TEMED). This system utilises two specific buffers 
for electrophoresis i.e. ananode buffer (0.2 M Tris, pH 8.9) and cathode buffer (0.1 M Tris, 
0.1 M Tricine, 0.1% SDS, pH 8.25). Electrophoresis was performed with the BioRad Mini-
Protean II gel apparatus (BioRad). Samples were boiled 10 minutes and then loaded into the 
wells. Electrophoresis was carried out at 30 V until the dye reached the separating gel and 
105V afterwards. LPS was visualised by silver staining (GE Heathcare). Immunotype L3,7,9 
LPS was detected using anti-L3,7,9 antibody (dilution 1:1000 NIBSC). Binding of a secondary 
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antibody (1:1000, anti-Mouse immunoglobulin conjugated to HRP; DakoCytomation) 
was detected using the enhanced chemiluminescence (ECL) system (Amersham 
Biosciences).  
 
2.6.4 Western blot analysis 
Protein or LPS samples were separated under reducing conditions by 12% 
SDS-PAGE, then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore) 
for 1 hr in cold transfer buffer (25 mM Tris, 190 mM glycine). After blocking 
membranes overnight in 5% milk in PBS, galectin-3 was detected by incubation of the 
membrane with rabbit anti-galectin-3poly-clonal antibodies (pAbs) (Santa Cruz 
Biotechnology, 300 ng/ml)or anti-actin (Sigma) for 1 hour at room temperature. 
Binding of the primary antibody was detected using an anti-rabbit-IgG HRP-
conjugated secondary antibody (1;1000 dilution; Santa Cruz BIothecnology), and ECL 
detection kit (GE Healthcare). 
Immunotype L3,7,9 was detected using α-L3,7,9 antibody (dilution 1:1000 
NIBSC). Binding of a secondary antibody (1:1000, anti-Mouse immunoglobulin 
conjugated to HRP, DakoCytomation) was detected using the ECL system (Amersham 
Biosciences). For preparation of samples, cells and supernatants were collected at 
different time points and cells were removed from wells using 0.5% trypsin/0.2% 
ethylenediaminetetraacetic acid (EDTA) or scraping, then washed with PBS and lysed 
at 100°C in SDS-PAGE buffer. 
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Table 2.4. Antibodies used for western blot analysis. 
Antibodies Source Concentration 
anti-L3,7,9 NIBSC 4.5 ng/ml 
anti-hGal-3 Rabbit poly-clonal (SCB) 300 ng/ml 
anti-hGal-3 Rabbit poly-clonal (Prof. Gabius) 1 µg/ml 
anti-rabbit IgG HRP SCB 1:1000 
anti-actin Sigma 1:1000 
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2.7 RNA procedures 
2.7.1 RNA isolation 
RNA was isolated from 1x106THP-1 or Detroit-562 cells cultured in 24-well 
plates as described in section 2.2. Supernatants were removed and cells washed 
twice with PBS, followed by addition of 200 µl of trypsin to detach cells. After 
detachment, fresh culture medium was added and cells were centrifuged 10 minutes 
at 300xg. Lysis buffer (Qiagen) was used to disrupt the cells and RNA was isolated 
using the RNAeasy Miniprep Kit (Qiagen) according to the manufacturer’s protocol. 
To determine the integrity of the RNA, samples were analysed by agarose gel 
electrophoresis; approximately 50 ng of RNA were combined with a 1:6 solution of 
gel loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol) 
and separated on 1% w/v agarose (Bioline, UK) gels in 1% Tris Acetate EDTA (TAE) 
buffer (0.4 M Tris, 0.01 M EDTA-Na2, 0.2 M acetic acid). RNA samples were stained 
with SYBR Safe (Invitrogen) and visualised with a UV transilluminator (Syngene 
GeneFlash, UK).The purity of RNA was analysed by measuring the A260 and A280 of 
samples, and RNA was stored at -80°C. 
 
2.7.2 Reverse transcription 
Elimination of genomic DNA present in RNA preparations and reverse 
transcription of RNA into complementary DNA (cDNA) were achieved using the 
Quanti Tect Reverse Transcription kit (Qiagen, UK) and following the manufacturer’s 
protocol. The kit provides a combined procedure for both reverse transcription and 
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genomic DNA elimination. Genomic DNA was removed by treatment with DNase I (Qiagen) 
and cDNA samples were stored at -20° C. 
2.7.3 Semi-quantitative Real Time PCR (qRT-PCR) 
Transcript levels were measured by qRT-PCR using QuantiFast with SYBR green 
detection (Qiagen) on a Rotor-Gene 3000 thermal cycler (Corbett Research), using 1 µl of 
cDNA samples corresponding to about 400 ng of cDNA. The following two-step real time 
cycling program was chosen for amplification: initial activation step for 5 minutes at 95°C, 
40 cycles of denaturation at 95°C for 10 seconds and combined annealing/extension at 60°C 
for 30 seconds. Fluorescence was acquired in the combined annealing/extension step. 
Results for the transcription of galectin-3 were normalised to levels for the housekeeping 
gene ß-actin. Primers for human galectin-3 (Forward 5’-TGTGCCTTATAACCTGCCTTT-3’, 
Reverse 5’-TTAAAGTGGAAGGCAACATCA-3’) and human ß-actin (Forward 5’-
GCACTCTTCCAGCCTTCCTTCC-3’, Reverse 5’-GAGCCGCCGATCCACACG-3’) were designed 
using the Primer3 website (http://frodo.wi.mit.edu/) and specificity checked performing a 
BLAST search (National Centre for Biotechnology Information, NCBI). Primers were designed 
so that one half hybridises to the 3’ end of one exon and the other half to the 5’ end of the 
adjacent exon, to allow annealing of those to the cDNA synthesised from the spliced mRNA 
and not to the genomic DNA, eliminating detection of contaminating DNA. Data were 
analysed using the Comparative Quantitation method by Rotor-Gene software (version 6.0; 
Corbett Research). Relative quantification determines the ratio between the amount of a 
target and the amount of a reference nucleic acid, the housekeeping gene. Controls 
included reactions with no template, and samples of RNA that had not been treated with 
reverse transcriptase; qRT-PCR was performed in triplicate on cDNA samples derived from 
three independent assays. 
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2.7.4 Small interfering RNA procedures 
The Amaxa transfection is an electroporation method based on the use of an 
electroporation machinery designed for mammalian cells and built by Amaxa (AAD-
1001, Amaxa Inc, Gaithersburg, USA). THP-1 cells were grown to confluency and 
harversted as in section 2.2. A total of 1x106 cells were required for each 
electroporation reaction. These cells were centrifuged at 1500 rpm for 8 minutes at 
room temperature and supernatants removed. Cells were transfected with an On 
Target plus SMARTpool of a four small interfering-RNAs (siRNA) designed specifically 
for galectin-3(Thermo Scientific Dharmacon).  
The RNA sequences targeted are: GGAGAGUCAUUGUUUGCAA, 
GUACAAUCAUCGGGUUAAA,GGCCACUGAUUGUGCCUUA, GGUGAAGCCCAAUGCAAA. 
Cells were transfected with 3 μg of siRNA using Nucleofector solution V (Dharmacon) 
according to the manufacturer’s instructions. Negative controls were carried out 
using buffer only.Cells were transferred to a 2 mm electroporation cuvette (Amaxa 
Inc, Gaithersburg, USA) and electroporation was carried out with a Nucleofector 
machine (VCA-1003, Amaxa) using the program V-01* / V-001** (suggested by the 
manufacturer for high efficiency THP-1 cell transfection). Following electroporation, 
cells were re-suspendedin culture medium supplemented with PMA for 24 hours to 
allow attachment. The medium was then replaced to remove dead cells and the cells 
were cultured for a further 48 hours to allow differentiation into macrophages. To 
confirm the silencing of galectin-3, western blot analysis was performed 72 hours 
after the initial transfection. Only cells with no detectable galectin-3 expression were 
used for experiments. 
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2.8 Preparation of human peripheral blood monocytes 
Human peripheral blood was extracted from healthy volunteers in accordance with 
local ethical research committee guidelines. Monocytes were isolated by adherence after 
Ficoll-Hipaque purification of peripheral blood mononuclear cells (PBMCs) (Bennett and 
Breit 1994). Blood was collected into EDTA-K2 coated tubes to avoid coagulation and 
subjected to density centrifugation on an equal volume of Histopaque 1077 gradient 
(density 1.077 g/ml, Sigma Aldrich) at 800xg for 30 minutes. After centrifugation, plasma 
was removed and the layer containing PBMCs was gently collected and transferred to a 50 
ml tube. 25 ml of PBS were added to PBMCs and samples were then centrifuged at 200xg 
for 10 minutes. The cells were washed twice with by a final step of 300xg for 10 minutes. 
Cells were enumerated between the second and the third wash, to determine number of 
cells to culture in 24 well plates. Approximately 10 % of the cells were monocytes present in 
a mixed population of lymphocytes and monocytes. Finally, cell pellets werere-suspended in 
1 ml of pre-warmed culture medium, gently washed and then seeded at 3x105 cells/ml in 24 
well plates in RPMI medium without FCS and allowed to adhere for 3 hours at 37°C, after 
which non adherent B and T cells were removed by extensive and thorough washing. Cell 
viability was estimated using the Trypan blue exclusion method and was higher than 95% on 
all occasions. Purity of monocytes was assessed using fluorescence microscopy by analysing 
nuclear shape (4,6-diamino-2-phenylindole (DAPI) staining) or by florescence ativating cell 
sorting (FACS) analysis, measuring surface expression of the CD14 receptorusing an anti-
human CD14 mouse monoclonal antibody (Abcam). 
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2.9 Whole Cell Enzyme Linked Immunosorbent Assay (ELISA) 
Wild-type THP-1 and siRNA galectin-3 cells differentiated with PMA were 
infected with N. meningitidisfor 4 hours. Cell supernatants were collected and 
initially centrifuged at 14000 rpm to remove bacteria and particulate material; 
supernatants were transferred to 0.22 µm filter columns (Sigma-Aldrich, Corning 
Costar) and centrifuged twice at 2000 rpm to eliminate residual bacteria. Samples 
were used immediately after filter sterilisation or stored at -20° C. The Human TNF-
α/TNFSF1A Quantikine kit (R&D Systems) was used to measure the concentration of 
TNF-α in supernatants and analysis was performed according to 
manufacturer’sguidelines. Recombinant TNF-α protein (R&D Systems) was used as a 
standardard at different concentrations. Standards, controls and supernatants were 
analysed in duplicate and the O.D. of controls containing only washing buffer was 
subtracted from the mean of the sample readings. The log of the TNF-α 
concentration versus the O.D. was plotted to build a standard curve and 
concentrations in the samples was calculated using the standard curve. The O.D. was 
measured using a micro-plate reader set at 450 nm (Multiscan Ascent, Thermo Life 
Sciences).  
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2.10 Flow cytometry 
For analysis by flow cytometry, bacteria were grown overnight on BHI agar then 
harvested into PBS. 2x108 CFU were fixed in 3%paraformaldehyde (PFA) for 2 hours at room 
temperature, washed three times in PBS, and stored at -80°C in PBS/15% glycerol. To 
measure human cell surface receptors THP-1, cells were removed from wells of tissue 
culture plates by scraping, washed in PBS and 2.5 x 105 cells were used for analysis.To 
measure galectin binding, 2x107 bacteria were incubated with 30 µl of label free or 
biotinylated galectin (Andre et al. 2007)at different concentrations for 1 hour at 37°C. When 
required, lactose or sucrose were added at a concentration of 100 or 300 mM. After two 
washes with PBS/Tween 0.1%, binding was detected by incubation with a rabbit anti-human 
galectin antibody (Lohr et al. 2008) for 45 min at 4°C or a mouse anti-biotin antibody 
(1µg/ml, Invitrogen). The cells were washed twice in PBS/Tween 0.1%, then resuspended in 
50 µl of PBS with a poly-clonal donkey anti-rabbit IgG-Cy2 conjugate (1/200 dilution in PBS; 
Jackson ImmunoResearch Laboratories) or a poly-clonal donkey anti-mouse IgG fluorescein 
isothiocyanate (FITC) conjugate (1/200 dilution; Jackson ImmunoResearch Laboratories) and 
incubated for 30 min on ice. Galectin binding was analysed using a flow cytometer (Calibur 
FACScan; BD Biosciences), and at least 4x104 events were recorded. Galectin-3 binding was 
expressed by calculating the Fluorescence Index (% positivebacteria gated multiplied by the 
geometric mean fluorescence).  
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Table 2.5 Antibodies used for flow cytometry. 
Antibodies Source Concentration 
anti-hGal-1 Rabbit poly-clonal (Prof. Gabius) 2 µg/ml 
anti-hGal-3 Rabbit poly-clonal (Prof. Gabius) 2 µg/ml 
anti-hGal-4 Rabbit poly-clonal (Prof. Gabius) 2 µg/ml 
anti-hGal-8 Rabbit poly-clonal (Prof. Gabius) 2 µg/ml 
anti-hGal-9 Rabbit poly-clonal (Prof Gabius) 2 µg/ml 
anti-hGal-3 Rabbit poly-clonal (SCB) 4 µg/ml 
anti-biotin Mousemono-clonal (Sigma) 1 µg/ml 
anti-rabbit IgG-Cy2 
Donkey poly-clonal (Jackson 
Immunoreasearch laboratories) 
1:200 
anti-mouse IgG-FITC 
Donkey poly-clonal (Jackson 
Immunoresearch Lboratories) 
1:200 
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2.11 Fluorescence and confocal microscopy 
For fluorescenceand confocal microscopy Detroit cells, human primary monocytes 
and THP-1 cells were seeded onto glass coverslips and infected with MC58 at a multiplicity 
of infection (MOI) of 30 or 50 for 1-4 hours at 37°C. Samples were washed twice with PBS, 
fixed for 20 minutes at room temperature in 3% PFA in PBS, and then washed three times in 
PBS. For labelling, bacterial cells were incubated for 1 hour with an anti-LPS antibody (α-
L3,7,9) and/or an anti-galectin-3 antibody (Santa Cruz Biotechnology) diluted in PBS/horse 
serum 1%, after which the cells were washed twice in PBS, then incubated for 30 minutes 
with an anti-mouseAlexa Fluor-488-conjugated antibody (Invitrogen) to label bacteria and 
an anti-human Alexa Fluor-555-conjugated antibody (Invitrogen) to label the cells. A DAPI 
staining was also performed to visualise the cellular nuclei, adding the dye (300 nM)with the 
secondary antobodies. After labelling, cells were washed twice in PBS and then ddH2O, 
mounted in Aqua Poly/Mount (Polyscience, Inc), and analysed by fluorescence microscopy 
(BX40, Olympus)or by laser-scanning confocal microscopy (Zeiss Axiovert LSM510). Images 
were processed using the ImageJ program (Image Processing and Analysis in Java). 
 
Table 2.6 Antibodies used for fluorescence and confocal microscopy. 
Antibodies Source Concentration 
anti-L3,7,9 Mouse (NIBSC) 90 ng/ml 
anti-hAlexa555 Donkey (Invitrogen) 1:200 
anti-mAlexa488 Donkey (Invitrogen) 1:200 
anti-hGal-3 Rabbit (SCB) 1:50 
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2.12 Adhesion and internalisation assays 
For adhesion and internalisation assays Detroit 562 cells, THP-1 cells 
with PMA and human primary monocytes from healthy volunteers were used. 
were seeded in 24 well plates at a concentration 5x105cells per well, and 2x105cells 
per well on coverslips for microscopy. Bacteria were harvested following overnight 
culture on solid media and re-suspended in 400 µl of PBS. The concentration of the 
suspension was calculated measuring the A260and adjusted in culture media to give 
the desired MOI. THP-1 and Detroit 562 were infected at an MOI of 30 for 1 hr at 
37°C, while human primary monocytes were infected at a MOI of 50 for 90 minutes 
at 37°C; when required, bacteria were pre-incubated with 30 µl of recombinant 
galectin-3 (3.3 μM) or PBS for 1 hr at 37°C. For adhesion assays, cells were washed 
extensively with PBS to eliminate non-adherent bacteria then lysed with 1% saponin 
for 10 min at 37°C to recover cell-associated bacteria. For internalisation assays, cells 
were washed with PBS to eliminate non-adherent bacteria and exposed to 
gentamicin (100 µg/ml) for 15 min to kill extracellular bacteria. Cells were washed 
extensively with PBS after gentamicin treatment to remove antibiotic and dead 
extracellular or non-bound bacteria, and subsequenlty lysed with saponin 1% or re-
incubated in medium for 1 or 2 hours. In both adhesion and internalisation assays 
serial dilutions of bacteria were plated to solid media following cell lysis or 
gentamicin treatment, and CFU were counted the following day. Bacteria recovered 
from cells without gentamicin treatment represented the total number of bacteria 
associated with cells; bacteria recovered from cells treated with gentamicin 
represented the number of internalised bacteria. Bacterial interaction with cells was 
calculated by measuring the percentage of cell associated bacteria relative to the 
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initial inocula used for challenge; bacterial internalisation was calculated by measuring the 
percentage of bacteria recovered after gentamicin treatment relative to the initial inoculum. 
In some assays results were normalised to the percentage of bacteria associated to cells 
when pre-incubated with PBS (indicated in figures as 100%).   
 
2.13 Statistical analysis 
Statistical significance was determined by using the Student’s Two-tailed unpaired t-
test or One-tailed paired Student’s t-test with the Graph Pad Prism v5 (GraphPad Software, 
California, USA). In both tests, Gaussian distributions were assumed.Statistical significance is 
indicated with asterisks where *=p<0.05, **=p<0.01 and ***=p<0.001. Exact p values are 
shown in the figure legends.  
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CHAPTER 3: Expression of galectins during meningococcal 
infection 
3.1 Galectins during meningococcal infection 
In this chapter studies were performed to determine whether infection with N. 
meningitidis leads to changes in the presence of galectins, a family of proteins modulated 
during bacterial infection and known to regulate leukocyte functions and inflammatory 
responses (Vasta 2009). A variety of cellular and in vivo models were employed to address 
this question. Although N. meningitidis is a human specific pathogen, rodent models have 
been used to represent certain stages of meningococcal disease, especially bloodstream 
disseminated infection (Li et al. 2006; Sjolinder et al. 2008). Therefore, initial studies were 
undertaken using tissues from mice that had been challenged with bacteria, and results 
compared with tissue from non-infected mice. Tissues obtained from patients with proven 
meningococcal disease were also examined.  
Particular emphasis was focused on galectin-3, the only chimera-type galectin, which 
is constitutively expressed in various human and murine tissues, and up-regulated in 
inflammatory conditions such as asthma, tissue damage and infection (Liu et al. 1995; Bellac 
et al. 2007; Oliveira et al. 2007). Galectins are expressed bya range of cell types, including 
phagocytes and epithelial cells, and given that N. meningitidis interacts with both these cell 
types in the nasopharyngeal mucosa, blood and brain, the presence of galectin-3 was also 
examined in phagocytic and epithelial cell lines.  
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3.2 Expression of galectins in mice infected with N. meningitidis 
In the first instance, the presence of galectins was examined in a murine model of 
systemic meningococcal infection. This and other models of bacteraemia have been 
developed for studying meningococcal infection, even though N. meningitidis is a human-
specific pathogen (Szatanik et al. 2011). In particular, a murine model has been used in 
previous studies to examinethe virulence of N. meningitidis strains (Li et al. 2004; Exley et al. 
2005; Tala et al. 2011), and to evaluate the efficacy of vaccine candidates (Li et al. 2009). 
Mice receive intraperitoneal iron dextran as an adjuvant to enable bacterial replication in a 
host which does not naturally provide an available iron source for the meningococcus 
(Szatanik et al. 2011).   
We analysed the expression of representative galectins belonging to each group of 
galectins in tissues during meningococcal infection: the proto-type galectin-1, the tandem 
repeat type galectin-4, and the chimera type galectin-3. Galectin-1 is found on the 
extracellular side of cell membranes and in the extracellular matrices of various normal and 
neoplastic tissues (Cooper and Barondes 1990); in particular, galectin-1 is widely distributed 
in the nervous system, human colon and in skeletal muscle (Kami and Senba 2005; Camby et 
al. 2006; Demetter et al. 2008). Less is known about the distribution of galectin-4 in tissues, 
although it has been identified in murine and porcine intestine (Rechreche et al. 1997; 
Rumilla et al. 2006).  
Human and murine galectin-3 share 78% of amino acid identity and are widely 
distributed in tissues of both species. In mice, galectin-3 is ubiquitously expressed, while in 
humans, galectin-3 is present in intestinal epithelial cells, kidneys, lungs, thymus and the 
pancreas (Flotte et al. 1983; Bao and Hughes 1995; Kasper and Hughes 1996; Villa-Verde et 
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al. 2002); galectin-3 is mostly found in neutrophils, eosinophils, basophils, Langerhans cells, 
monocytes and macrophages from the various tissues.   
Using antibodies raised against human galectins that cross-react with murine 
galectins (Kaltner et al. 2002; Lohr et al. 2008), the presence of galectins was analysed in 
spleen tissue 24 hours after challenge of mice with the serogroup B N. meningitidis isolate 
MC58 and findings were compared to those obtained with tissues from uninfected mice. 
Immunohistochemical analysis was performed with the help of Dr. Yanwen Li (Imperial 
College).Galectin-1 and galectin-4 were not detected in the tissues (Fig. 3.1 B and D) or 
present only at low levels (Fig. 3.1 A and E), and there was no obvious difference between 
tissuesfrom infected and un-infected mice. In contrast, although weak galectin-3 staining 
was present especially in the spleens from uninfected mice (Fig. 3.1 C), a marked increased 
staining was observed in a large number of cells in the spleens of mice challenged with N. 
meningitides (Fig 3.1 F). The increase in galectin-3 staining coincided with the presence of N. 
meningitidis in the spleen tissue (not shown). Therefore these data indicate that the level of 
galectin-3 increases during meningococcal infection in the spleen, an organ that contains 
predominantly immune cells such B and T cells, resident and infiltrating macrophages or 
monocytes (Weih and Caamano 2003). 
Galectin-3 is expressed ubiquitously and actively secreted by inflammatory 
macrophages, mast cells and epithelial cells (Sato et al. 1993; Sato and Hughes 1994; Craig 
et al. 1995). We therefore extended our study to examine the expression of galectin-3 in 
further murine tissues following infection with N. meningitidis. Meningococcal disease leads 
to myocardial depression, pneumonia, and bacteria have been detected in the liver and in 
pancreas (Danielsson et al. 1971). Therefore, the expression of galectin-3 was examined in 
samples of cardiac, lung and liver tissue from infected animals. As shown in Fig. 3.2, intense 
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staining, with a large number of cells positive for galectin-3 was observedin all tissues 
examined. In particular, positive signal was rarely seen in myocardial tissue from control 
mice, while intense signals that might correspond to infiltrating PMNs and macrophages 
were observed in cardiac tissue from infected mice. In the liver, some Kupffer cells were 
positive for galectin-3 in control tissues, while almost all Kupffer cells stained intensely 
following infection. In addition, weak signals for galectin-3 were detected in the pancreas of 
control mice, while intense staining was observed in infected mice. Therefore, 
meningococcal infection is associated with a marked increase in detectable galectin-3 in all 
tissues examined. 
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Figure 3.1 Expression of galectins in the spleens of mice infected with N. meningitidis. 
Detection of galectin-1 (A, D), galectin-4 (B, E) and galectin-3 (C, F) in spleens of mice 24 hrs 
after infection with N. meningitidis serogroup B strain MC58 in iron/dextran (infected) and 
in spleens of mice challenged with iron/dextran (uninfected). Galectins were detected with 
rabbit anti-galectin-1, -3 and -4 antibodies. Galectin-1 and galectin-4 were either not 
detected (B and D) or present at low levels (A and E) in uninfected and infected tissues. 
Galectin-3 (brown staining) was detected in a few cells of control tissues (C), while marked 
staining was observed in tissues from infected mice (F). Scale bars correspond to 10 µm. 
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Figure 3.2 Expression of galectin-3 in organs from mice infected with N. meningitidis. 
Detection of galectin-3 in the heart, liver, lung and pancreasfrom mice 24 hrs after infection 
with N. meningitidis serogroup B strain MC58 in iron/dextran (infected) or iron/dextran only 
(uninfected). Galectin-3 was present at low levels in control mice (A, B, C, D) with the signal 
increased (brown staining) in infected tissues (E, F, G, H). Scale bars correspond to 10 µm. 
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3.3 Expression of galectin-3 in the brain from mice infected 
with N. meningitidis 
N. meningitidis is a major cause of bacterial meningitis, which is inflammation of the 
meninges that surround the brain and the spinal cord (Tunkel and Scheld 1993; Fitch and 
van de Beek 2008). Therefore the presence of galectin-3 in the CNS of infected mice was 
examined insections of cerebellum, meninges and choroid plexus (Fig. 3.3). Galectin-3 was 
not detected in the cerebellum or meninges of uninfected mice, but was found in the 
choroid plexus, where it is present in the cuboidal epithelial cells (Fig. 3.3, A, C, E). While 
galectin-3 expression did not change appreciably in the choroid plexus upon infection (Fig. 
3.3, F), it was markedly increased in both the cerebellum and meninges (Fig. 3.3 B, and D). 
N. meningitidis infection causes a severe inflammation of brain tissue (Fowler et al. 
2006b) and the acute inflammatory response during bacterial meningitis is characterised by 
the recruitment of neutrophils from the bloodstream to the CSF, followed by mononuclear 
cells and activation of local microglia (Hoffman and Weber 2009). Galectin-3 up-regulation 
observed in some sections of the brain may reflect this inflammatory response, although the 
specific cell types expressing the lectin were not analysed in this study using specific 
antibodies. 
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Figure 3.3 Galectin-3 in the brain of mice following infection with N. meningitidis. 
Detection of galectin-3 in murine brain sections following 24 hours infection with N. 
meningitidis serogroup B strain MC58 in iron/dextran (infected) or with iron/dextran 
only (uninfected). Galectin-3 is not present in cerebellum (A) and meninges (C) from 
control mice. Brown staining corresponding to galectin-3 is observed in the 
cerebellum of infected mice (B), while diffuse signal is observed in infected 
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meninges. Some galectin-3 is observed in uninfected and infected choroid plexus (E 
and F). Scale bars correspond to 50 µm. 
 
3.4 Detection of galectin-3 in tissues from patients with 
meningococcal infection 
Having detected the presence of galectin-3 in different organs of mice infected with 
N. meningitidis, we proceeded with immunohistochemical analyses of galectin-3 expression 
in human tissues during meningococcal infection.  
Initially spleens from patients with meningococcal disease were examined (Fig. 3.4, 
B, C, E). Tissues were obtained from a post-mortem studyin Cote d’Ivoire in 1993 and kindly 
supplied by Professor Lucas, St. Thomas Hospital (Lucas et al. 1993). The staining for 
galectin-3 was performed on two different patients. Meningococcal infection was defined 
by immunohistochemistry (IHC) using antibodies to detect N. meningitidis and by PCR using 
DNA extracted from the tissue (not shown, performed by Yanwen Li) as a microbiological 
diagnosis was not available. Splenic tissue from a patient who died from a non-infection 
condition (car accident) was used as a control (Fig. 3.4 A and D). Similar to murine tissue, 
intense galectin-3 staining was observed in tissues from the patient but not in tissue from 
the control subject. Closer inspection revealed that galectin-3 is present in low levels in 
control tissues (Fig. 3.4, D), but is markedly increased in samples from the patient (Fig. 3.4, 
E), with accumulation of the protein evident both within cells and extracellularly.The 
presence of galectin-3 in the extracellular space in both murine and human tissues indicates 
release of the protein during meningococcal infection,where it is accessible to interact with 
extracellular bacteria. Therefore we performed immunohistochemical analysis of human 
spleen tissue from patients to detect galectin-3 and bacterial colonies (using an antibody 
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specific for N. meningitidis) in serial sections. There was clear co-localisation of galectin-3 
(Fig. 3.5 A) with bacteria (Fig. 3.5 B) within tissues,seen both at lower and higher 
magnification. 
To examine the specificity of galectin expression in human tissue in response to N. 
meningitidis infection, we also analysed the presence of galectin-7 (proto-type galectin) 
using an anti-galectin-7 antibody that recognises the human version of this protein by IHC. 
Galectin-7 expression was not detected in the infected tissues, although non-infected 
control tissueswere not examined (Fig. 3.4 C). 
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Figure 3.4 Galectin-3 expression in the spleen from patients with meningococcal disease. 
Sections of spleens were stained for the presence of galectin-3 (brown staining) or galectin-
7. Galectin-3 was detected in the patient (B and E) but only low levels were present in 
control tissue (A and D); galectin-7 was not detected (C). Higher magnification reveals diffuse 
staining corresponding to extracellular galectin-3 that surrounds cells, and intracellular 
galectin-3 contained in immune cells. Images are from one patient. Scale bars correspond to 
10 µm. 
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Figure 3.5 Co-localisation of galectin-3 and N. meninigitidis in the spleen from patients 
with meningococcal infection. 
Immunohistochemical staining of spleen tissue showing co-localisation of bacterial 
colonies and galectin-3. Serial sections of spleen tissue were stained with a rabbit anti-
human galectin-3 antibody (brown in A and C) or a polyclonal antibody against N. 
meningitidis (red in B and D). Intense accumulation of brown staining is seen in the 
spleen at different locations (A and C, arrows). Red staining corresponding to N. 
meningitidis (B and D, arrows) occurs at the same location as the accumulations of 
galectin-3. The higher magnificationconfirmed this co-localisation, and shows galectin-3 
in individual cells and extracellularly in a pattern similar to that observed in infected 
murine tissues. Scale bars correspond to 50 µm in A and B, and to 10µm in C and D. 
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3.5 Expression of galectin-3 in human phagocytes 
In summary, there was a clear increase in galectin-3 staining in both murine and 
human tissue following infection with N. meningitidis; the staining occurred both 
intracellularly and extracellularly, and co-localised with bacterial colonies. However, 
although it is known that galectin-3 is expressed by immune cells, and that these types of 
cells are usually present during infection, it was not possible to evaluate whether staining 
was due to increased galectin-3 expression by resident cells (triggered by meningococcal 
infection) or recruitment of galectin-3 expressing cells to the infected tissue. Intense 
staining was seen in the spleen, which is replete with phagocytic cells, and in the meninges 
which are infiltrated with phagocytes during meningococcal infection (Nielsen et al. 1988; 
Arevalo et al. 1989). In addition, galectin-3 expression by macrophages and monoctes in vivo 
has been previously reported (Reichert and Rotshenker 1999; MacKinnon et al. 2008). 
Therefore we analysed theexpression of galectin-3 by phagocytes such as monocytes and 
macrophages in vitro using a human monocytic cell line (THP-1) and human primary 
monocytes obtained from whole blood. The macrophage-like cell line THP-1 has been used 
extensively as a representative model of human phagocytes (Borrmann et al. 2011; Estrella 
et al. 2011; Qin 2011; Zughaier 2011). Human primary monocytes obtained from whole 
blood were separated by adherence (Bennett and Breit 1994), and identified by nuclear 
staining and the presence of CD14 on the cell surface by flow cytometry (data not shown). 
CD14 is a monocyte receptor and is up-regulated upon activation and differentiation 
(Ziegler-Heitbrock 2007). CD14 positive monocyte derived progenitor cells can be isolated 
from PBMCs and are characterised by slow proliferation in absence of growth factors and by 
the expression of surface markers including CD14, CD35 and CD45 (Zhao et al. 2003). 
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Furthermore, they are able to differentiate into different cell lineages including osteoclasts, 
chondrocytes, myocytes and endothelial cells (Kuwana et al. 2003). 
Galectin-3 was previously known as Mac-2 and used as a cell surface antigen marker 
for mature macrophages, while levels of galectin-3 in THP-1 cells are known to be enhanced 
upon PMA activation (Kim et al. 2003). THP-1 cells were differentiated into macrophages by 
exposing them to PMA for 72 hours, and western blot analysis performed on cell lysates of 
undifferentiated and differentiated cells; cellular actin was detected as a control. There was 
a clear increase in the amount of galectin-3 in differentiated cells compared to 
undifferentiated cells, consistent with previous results ((Kim et al. 2003),Fig. 3.6 A). Next, 
galectin-3 mRNA and protein levels were analysed in differentiated THP-1 macrophages 
infected with N. meningitidis isolate MC58 at an MOI of 30 for 3, 7 and 24 hours to examine 
whether bacterial infection modulates galectin-3 expression. Western blot analysis and qRT-
PCR analysis of galectin-3 mRNA level were compared with the expression of the 
housekeeping gene, β-actin. As shown in Fig. 3.6 B, the level of galectin-3 mRNA was similar 
in uninfected and infected cells at all the time points examined, indicating that there was no 
modulation of galectin-3 mRNA level upon infection with N. meningitidis. In addition, similar 
levels of protein were observed in all samples at each time point, suggesting that 
endogenous galectin-3 is not affected by N. meningitidis infection (Fig. 3.6 C). Galectin-3 was 
not detected in supernatants of THP-1 cells, indicating that concentrations were either 
below the level of detection or a lack of galectin-3 release by THP-1 macrophages upon 
infection (Fig. 3.6 C). 
Next, the surface expression of galectin-3 on differentiated THP-1 cells was 
examined. Galectin-3 binds to receptors present on the surface of cells, such as T cell 
receptor β (TCR- β) or CD98 on T cells and macrophages, respectively (Dong and Hughes 
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1996; Rabinovich et al. 2002), and some receptors belonging to the CEACAM family on 
neutrophils(Ohannesian et al. 1995). Therefore to examine the saturation of galectin-3 
receptors present on the surface of THP-1 macrophages, recombinant galectin-3 (3 µg) was 
added to cells. No increase in the level of surface bound galectin-3 was detected following 
addition of exogenous protein, indicating that there were no unoccupied receptors on the 
surface of THP1 macrophages (Fig. 3.7). In addition, preliminary data on human primary 
monocytes, revealed that these cells do not express detectable amounts of galectin-3 on 
their surface, while incubation of the cells with exogenous recombinant galectin-3 led to 
detectable galectin-3 on the surface, indicating that galectin-3 is able to bind receptors on 
these cells (not shown). 
Our data thus confirm the expression of galectin-3 on the surface of THP-1 cells and 
human monocytes (Novak et al. 2011), and suggest that galectin-3 may interact with surface 
ligands or receptors on phagocytic cells. 
The expression of galectin-3 on the surface of phagocytes was also examined by 
immunofluorescence microscopy using an anti-galectin-3 antibody to detect galectin-3on 
THP-1 cells or human primary monocytes infected with GFP-expressing N. meningitidis 
MC58. Cells were stainedwithout permeabilisationto analyse surface expression. Figure 3.8 
shows diffuse galectin-3 staining in both human monocytesand THP-1 cells incubated with 
MC58 strain for 1 hour. Galectin-3 staining on primary human monocytes was less intense 
than on THP-1 macrophages, in accordance with our previous flow cytometry results (not 
shown). Furthermore, we observed N. meningitidis associatedwith the cell surface as the 
extracellular non bound bacteria were removed by washing the cells, consistent 
withprevious work(McNeil et al. 1994; Read et al. 1996; Spinosa et al. 2007). 
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Figure 3.6 Galectin-3 mRNA and protein expression in THP-1 macrophages. 
 (A) Galectin-3 levels in THP-1 cellsdetected by western blot prior to and following 
differentiation into macrophages by PMA. Lysates from 1x106 cells were subjected to SDS-
PAGE and analysed using an anti-galectin-3 antibody. (B) The relative amount of galectin-
3 mRNA in infected (black bars) and uninfected (grey bars) THP-1 macrophages, measured 
byqRT-PCR. Galectin-3 mRNA levels are comparable in infected and uninfected cells at 3, 
7, 24 hours following infection with N. meningitidis MC58. Values were normalised to 
results for the β-actin gene. (C) Galectin-3 detected by western blot analysis of THP-1 cells 
differentiated with PMA and in cell supernatants. Lysates from 1x106 cells were subjected 
to SDS-PAGE and western blotting using an anti-galectin-3 antibody. There is no obvious 
difference in the amount of galectin-3 detected in cells infected with N. meningitidis 
strain MC58; no galectin-3 was detected in cell supernatants. 
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Figure 3.7 Surface expression of galectin-3 on THP-1 macrophages. 
Flow cytometry analysis of galectin-3 on the surface of THP-1 macrophages before or after 
incubation of cells (5x105) with recombinant galectin-3 (3 µg). Galectin-3 is expressed on 
the surface of THP-1 cells and addition of exogenous galectin-3 does not alter the amount 
of galectin-3 detected. Experiments were performed in duplicate and error bars show the 
standard deviation. Data are from one representative experiment. 
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Figure 3.8 Detection of galectin-3 in THP-1 macrophages and monocytes by 
immunofluorescence microscopy. 
Epi-fluorescence microscopy showing surface expression of galectin-3 and bacterial 
association with phagocytic cells. Galectin-3 (red) is expressed by THP-1 cells and human 
primary monocytes and is present on the cell surface. N. meningitidis (green, arrows) 
associates with the cells. Scale bars correspond to 10 µM. 
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3.6 Expression of galectin-3 in epithelial cells 
Galectin-3 is expressed by several human cell types other than macrophages, 
including fibroblasts, endothelial cells or epithelial cells (Dumic et al. 2006). In particular 
galectin-3 is present in epithelial cells from the intestine, conjunctiva, lung, kidney, breast 
and prostate (Lotz et al. 1993; Bao and Hughes 1995; Castronovo et al. 1996; Kasper and 
Hughes 1996; Pacis et al. 2000; Hrdlickova-Cela et al. 2001). Nasopharyngeal epithelial cells 
are among the first cells encountered by N. meningitidis during colonisation (Trivedi et al. 
2011), and may represent a site of contact between bacteria and galectin-3.However, little 
is known about the expression of galectin-3 in the human nasopharynx (Saussez et al. 
2008a), and there are no data regarding its modulation during infection. 
We were unable to obtain tissue sections from the nasopharynx of infected 
individuals as it is not routinely examined in post-mortem studies. Therefore the expression 
of galectin-3 was examined in a human pharyngeal epithelial cell line as a model of the cells 
encountered by N. meningitidis during colonisation. Detroit 562 cells were grown in the 
wells oftissue culture plates with or without challenge with N. meningitidisMC58 at an MOI 
of 30. Expression of galectin-3 was not altered after 4 or 24 hours of infection (Fig. 3.9, A 
and B); cellular actin levels were used as a control. To further examine the expression of 
galectin-3 in Detroit 562 cells, we performed epi-fluorescence microscopy of uninfected and 
infected cells. Analysis of non-permeabilised cells demonstrated the surface expression of 
galectin-3 (Fig. 3.9 C). Furthermore, apparent co-localisation of bacteria and surface 
galectin-3 was observed by confocal microscopy, with diplococci in proximity to galectin-3, 
suggesting a possible interaction between N. meningitidis and endogenous galectin-3 at the 
site of bacterial attachment. 
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Figure 3.9 Galectin-3 expression and localisation in Detroit 562 cells infected with N. 
meningitidis. 
(A) Relative amount of galectin-3 mRNA in infected (black bars) and uninfected (grey bars) 
Detroit 562 epithelial cells measured by qRT-PCR. Cells were infected at an MOI of 30. Values 
were normalised to results for expression of the β-actin housekeeping gene. (B) Western 
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blot analysis showing galectin-3 and β-actin in infected (MC58) and uninfected (Control) cells 
4 or 24 hrs after challenge. (C) Fluorescence (C) and confocal (D) microscopy images of 
Detroit 562 cells stained for galectin-3 (red) and bacteria (green). Bacteria and galectin-3 
were stained following 1 hour incubation with a mouse monoclonal anti-LPS antibody (α-
L3,7,9) and a rabbit polyclonal anti-galectin-3 antibody, then incubated for 30 minutes with 
an anti-mouse Alexa Fluor 488 conjugated antibody to label bacteria and an anti-rabbit Alexa 
Fluor-555 conjugated antibody to label galectin-3 on the cell membranes. Accumulation of 
extracellular galectin-3 is observed in proximity of meningococci, suggesting co-localisation. 
Scale bars correspond to 10 µM in first panel and 1 µM in the subsequent panels.  
  
95 
 
3.7 Summary 
In this chapter the presence of different galectins in tissue during meningococcal 
infection was analysed in a murine model of meningococcal sepsis, and the expression of 
galectin-3 in human tissue, in phagocytes and epithelial cells was examined. Galectin-3,but 
not galectin-1 and galectin-4, is present in murine tissue during meningococcal infection. 
This observation was confirmed by immunohistochemical analyses of tissues from patients. 
Of note, galectin-3 was detected both in cells and extracellularly, and there was clear co-
localisation of this galectin with N. meningitidis in the spleen of patients with meningococcal 
disease. In addition, galectin-3 is expressed at both transcriptional and protein levels in the 
macrophage-like cell line THP-1 and the nasopharyngeal epithelial cell line Detroit 562. 
Furthermore, although N. meningitidis does not influence mRNA expression in phagocytes 
and epithelial cells, the presence of the protein was confirmed by microscopy, and there 
was some co-localisation of surface galectin-3 and N. meningitidison epithelial cells. 
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CHAPTER 4: Binding of galectin-3 to N. meningitidis 
 
In the preceeding chapter, galectin-3 was shown to be present in tissues from mice 
challenged with N. meningitidis, and patients with meningococcal disease: galectin-3 co-
localised with bacterial colonies. Furthermore, galectin-3 was present in the extracellular 
environment in infected tissues, consistent with the hypothesis that galectin-3 interacts 
directly with N. meningitidis. Therefore, in this chapter the binding of galectin-3 to bacteria 
was examined. As a range of galectins are produced during inflammation (Liu and 
Rabinovich 2010), and there are numerous sites of inflammation during meningococcal 
disease, the interaction between bacteria and several galectins belonging to different 
families was examined.  
 
4.1 Binding of N. meningitidis to galectins 
Galectins can be secreted into the extracellular milieu, where they are able to bind 
galactoside containing molecules on the surface of cells or micro-organisms (Dumic et al. 
2006). Initial binding experiments were performed with the serogroup B N. meningitidis 
strain MC58 (Virji et al. 1992a), which expresses an L3,7,9 immunotype LPS (Wakarchuk et 
al. 1996; Jennings et al. 1999). 
The binding of four galectins belonging to the different families was examined: 
galectin-1 and galectin-7 (proto-type galectins), galectin-4 (tandem repeat galectin), and 
galectin-3 (chimera-type galectin). These galectins are present in the cytoplasm of cells, but 
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can be released under certain conditions, and could potentially interact with bacteria in the 
extracellular environment (Rabinovich and Vidal 2011). 
In preliminary experiments, bacteria were fixed in paraformaldehyde (2x107 CFU) and 
incubated with galectin-3 at a range of concentrations (0.33 µM, 1.6 µM, 3.3 µM).Binding 
was detected by FACS analysis using galectin-3 at a concentration of 3.3 µM. Therefore this 
concentration was used in all experiments with this and other galectins, unless otherwise 
stated, as they have similar affinities for their ligands (Kaltner et al. 2002; Saussez et al. 
2005; Lohr et al. 2007). Indeed the affinities of ligands for immobilised galectin-1, -3, -4 and 
-7 have Kd of between 1 and 5 µM (Cederfur et al. 2008). Additionally, stoichiometry and 
analysis of galectin-ligand interactions indicates that a minimum concentration of 1.25 µM is 
required for binding of galectin-1 to its ligands (Earl et al. 2010). 
There was significant binding of galectin-3 to N. meningitidis, while none of the other 
galectins bound bacteria to any appreciable extent (Fig. 4.1, A and B). The lack of detectable 
binding of galectins other than galectin-3 underlines the specificity of binding, and directed 
us to characterise the interaction between N. meningitidis and galectin-3 in more detail.  
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Figure 4.1 Binding of N. meningitidis to galectins. 
(A) Representative flow cytometry traces showing binding of recombinant galectin-3 (Gal-3), 
galectin-1 (Gal-1), galectin-4 (Gal-4) and galectin-7 (Gal-7) to N. meningitidis following 
incubation of MC58 with galectins (3.3 µM). Negative controls (no galectin) are shown in 
grey, and traces in the presence of a galectin are shown in red. (B) Quantification of flow 
cytometry analysis of galectin binding to N. meningitidis. Binding is expressed as the 
Fluorescence Index (% positive bacteria gated multiplied by the geometric mean 
fluorescence). Data are from four different experiments and error bars show the standard 
deviation.  
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4.2 Effect of lactose on galectin-3 binding to N. meningitidis 
As mentioned in the introduction, galectin-3 interacts with various ligands via their 
LacNAc residues, and this interaction is mediated by the CRD of galectin-3, and can be 
inhibited by exogenous lactose. Galectin-3 is defined as a galactoside-binding protein and its 
principal ligands include lactose, N-acetyl-lactosamine and poly-lactosamine, while 
multivalent ligands increase the affinity of interactions (Diehl et al. 2010). 
To examine whether the interaction between N. meningitidis and galectin-3 is 
mediated by the CRD, binding studies were performed in the presence of lactose or sucrose. 
Consistent with carbohydrate dependent binding of galectin-3 to N. meningitidis, the 
interaction was significantly inhibited by lactose at a concentration of 100 mM (Fig. 4.2 
A,75% reduction of galectin-3 binding, p=0.0062). In contrast, addition of sucrose, a 
disaccharide that does not inhibit CRD-mediated binding (Ochieng et al. 1998b) had no 
effect (Fig. 4.2 B). Characterisation of the lactose inhibition was confirmed by titrating 
concentrations of lactose and recombinant galectin-3. Results demonstrate that lactose 
inhibits galectin-3 binding to N. meningitidis in a concentration dependent manner, with 300 
mM of lactose inhibiting the interaction in the presence of 3.3 µM of galectin-3 (Fig. 4.2C, D 
and E). Moreover, this concentration of lactose inhibited the binding of galectin-3 to fixed 
bacteria (2x107 CFU) over a range of concentrations of recombinant galectin-3 (Fig. 4.2 D). 
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Figure 4.2 Galectin-3 binding to N. meningitidis. 
(A) Quantification of flow cytometry analysis of galectin-3 (3.3 µM) binding to N. 
meningitidis in the absence or presence of 100 mM lactose. Lactose significantly reduces 
binding to N. meningitidis (Two-tailed, Unpaired Student’s t test, * p=0.0062. Data are from 
four different experiments performed in duplicate and error bars show the standard 
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deviation (B) Quantification of flow cytometry analysis of galectin-3 (3.3 µM) binding to N. 
meningitidis in the absence of disaccharides or presence of 100 mM lactose or sucrose. (C) 
Incubation of N. meningitidis with increasing concentrations of biotinylated galectin-3 
shows dose dependent binding to MC58 (black traces) which is inhibited by the presence of 
300 mM lactose (grey filled traces). (D) Quantification of galectin-3 binding to N. 
meningitidis in absence (black bars) or presence (grey bars) of 300 mM lactose over a range 
of galectin-3 concentrations (indicated). (E) Quantification of flow cytometry analysis of 
galectin-3 binding to N. meningitidis using galectin-3 at a concentration of 3.3 μM and 
increasing concentration of lactose (50, 100, 200, 300 mM). Binding is expressed as the 
Fluorescence Index. Experiments were performed in duplicate and error bars show the 
standard deviation.Results were consistent on at least three occasions; data are from one 
representative experiment. 
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4.3 Binding of N. meningitidisto galectin-3 from different species 
and effect of galectin-3 phosphorylation 
Of all galectins, galectin-3 is the most conserved as it is found in rodents, and 
chickens, as well as in other species (Kaltner and Gabius 2012). As binding of galectin-3 to N. 
meningitidis involves the CRD which is highly conserved across species, binding of the 
meningococcus to galectin-3 from non-human sources was investigated. Murine galectin-3 
shares 78% sequence identity with human galectin-3, while the CRD of chicken galectin-3 is 
68% identicalto the CRD of human galectin-3. Results show that chicken and mouse galectin-
3 bind to N. meningitidis at similar levels as human galectin-3, confirming the conservation 
of the binding sites of galectin-3 molecules from these species (Fig. 4.3).  
Galectin-3 is the only chimera type galectin, formed by a CRD connected to a N-
terminal region via repeated five repeats of a six amino acid sequence rich in Gly, Tyrand Pro 
which is sensitive to metalloproteinases((Ochieng et al. 1998a; Krzeslak and Lipinska 2004) 
and Fig. 1.6 A). The CRD is composed of 130 amino-acids, forming a globular structure with 
two anti-parallel β-sheets of five and six β-strands, respectively (Fig. 1.6 B). The ND has a 
short sequence (12 residues) that can be phosphorylated at Ser5 and Ser11, although the 
functional significance of this is not fully understood (Fig. 1.6 A). The phosphorylated form 
of galectin-3 is found in both the cytoplasm and nuclei of cells, while the non-
phosphorylated form is present only in the cytoplasm (Mazurek et al. 2000). 
Phosphorylation reduces binding to some ligands such as asialomucin and laminin (Yoshii et 
al. 2002). As this post-translational modification may affect the binding properties of the 
lectin, analysis of the binding of bacteria to human phosphorylated galectin-3 was assessed. 
Preparation of galectin-3 phosphorylated at Ser5 and Ser11 was performed in collaboration 
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with Professor Gabius using constitutively active casein kinase 1 (CK-1) and confirmed by 
mass spectrometry (Kubler et al. 2008). Flow cytometry results showed no significant 
alteration in the interaction of galectin-3 with the meningococcus upon phosphorylation 
(Fig. 4.3, p=0.1888) with the binding of bacteria to phosphorylated galectin-3 comparable to 
the binding to the non-phosphorylated protein. These data indicate that phosphorylation at 
Ser5 and Ser11 does not affect the selectivity of galectin-3 for N. meningtidis, consistent with 
the observation that the phosphorylated protein can still retain its binding properties and 
maintain its carbohydrate-inhibitable activity (Kubler et al. 2008).  
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Figure 4.3 Phosphorylated and galectin-3 from several species bind to N. meningitidis. 
Quantification of FACS analysis of binding to N. meningitidis using human galectin-3 
(hGal3), chicken galectin-3 (chGal3), mouse galectin-3 (mGal3) and phosphorylated human 
galectin-3 (pk Gal3) (3.3 μM of each protein). No significant difference was observed in 
binding to the different galectins.  
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4.4 Characterisation of the binding between N. meningitidis and galectin-3 
 
4.4.1 Galectin-3 domains involved in binding 
The biological activities of galectin-3 in the extracellular compartment are mainly 
dependent on its interaction with various ligands via CRD (Ochieng et al. 2004). However, 
the ND of galectin-3 can interact with non-carbohydrate molecules in the cytoplasm or 
nucleus such as Gemin-4, K-Ras or Synexin (Haudek et al. 2009). Furthermore the ND of 
galectin-3 has been suggested to interact with a region of Salmonella LPS that includes part 
of the lipid A and the inner core (Mey et al. 1996). Additionally, several lines of evidence 
indicate that galectin-3 binding to glycoproteins involves the concentration and time 
dependent formation of pentamers, through the association between NDs, which increases 
the affinity for the ligand.  
Results from section 4.3 indicate that the CRD of galectin-3 binds meningococci, as 
lactose partially inhibits binding. However, to establish whether further domains of galectin-
3 are necessary for the interaction with N. meningitidis, we examined the binding of 
truncated galectin-3, in which the N-terminal region had been removed by proteolytic 
treatment with collagenase D which cleaves at Met127, as described previously ((Kopitz et al. 
2001), Fig. 1.6 A and 4.4). This treatment leaves the CRD (residues 127-264) of the protein 
intact and functional (Agrwal et al. 1993).  
As shown in Fig. 4.5, proteolytic removal of the N terminal section of galectin-3 
abolished binding to wild-type strain MC58 (p=0.0016), indicating that the CRD alonewas 
not sufficient to support galectin-meningococcal interactions, and that the N-terminal 
region of the protein is necessary for binding. A concentration of 3.3 µM for both full length 
106 
 
and truncated galectin-3 was used in the assay. These data are consistent with 
oligomerisation of the protein being necessary for galectin-3 binding to the meningococcus 
or with the ND itself being involved in the interaction of full length galectin-3 with N. 
meningitidis. 
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Figure 4.4 Cleavage sites in galectin-3. 
Schematic representation of the mRNA and domain structure of galectin-3. The gene 
encoding galectin-3 is formed by six exons and five introns where the exons I and II encode 
the 5’ untranslated region, exon III encodes the ND and exons IV, V and VI encode the CRD. 
The N-terminal domain of about 130 amino acids rich in Pro-Gly-Arg-Tyr residues (ND, dark 
grey) and carbohydrate recognition domain of about 130 amino acids (CRD, light grey) are 
indicated. The ND of the protein is removed by treatment with collagenase D.  
 
  
108 
 
 
 
 
Figure 4.5 Binding of truncated galectin-3 to N. meningitidis. 
Representative flow cytometry traces showing binding of full length galectin-3 (3.3 µM) to 
N. meningitidis (black trace, FL Gal-3) and galectin-3 consisting of the CRD alone (3.3µM, 
black trace, Tr Gal-3), with the negative control (no galectin-3) shown in grey. (B) 
Quantification of flow cytometry analysis of binding of full length galectin-3 and truncated 
galectin-3 to N. meningitidis MC58. Tr Gal-3 binding to N. meningitidis is significantly 
reduced compared to the full length protein (Unpaired Student’st test, p=0.0016). Data are 
from four different experiments and error bars show the standard deviation. The binding is 
expressed as the Fluorescence Index. 
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4.4.2 Full length LPS is required for galectin-3 binding to N. meningitidis 
In almost all Gram negative bacteria which have been reported to bind galectin-3, 
the target ligand is LPS (Mey et al. 1996; Gupta et al. 1997; Fermino et al. 2011); this 
includes the LPS of N. gonorrhoeae. Therefore it was likely that LPS is involved in the 
attachment of galectin-3 to the meningococcal surface.  
Meningococcal LPS consists of lipid A, which anchors the molecule in the outer 
membrane (Fig 1.3 A) and an oligosaccharide portion. Lipid A contains five acyl chains joined 
to two glucosamine residues (Erridge et al. 2002). These are linked by two Kdoresidues to an 
oligosaccharide with an inner core di-heptose-N-acetylglucosamine backbone;the two Hep 
residues provide the point of attachment for a variety of outer core oligosaccharides 
(Monteiro et al. 2003). The outer core is formed by Gal, GlcNAc and Gal, and includes LNnT, 
the last two residues of which constitute LacNAc, a known galectin-3 ligand (Cederfur et al. 
2008). The addition of HepII and GlcNAc to HepI (with or without substitutions) defines the 
α-chain, while the addition of Glc to the HepI and the whole outer core defines the β-
chain.In addition, Neu5Ac (Fig 1.3 A) can be attached to LPS at the terminal Gal of certain 
LPS immunotypes (Gilbert et al. 1997).  
Galectin-3 has affinity forLac and LacNAc, but also for larger oligosaccharides 
including those containing poly-N-acetyl-lactosaminoglycan (Leffler and Barondes 1986; 
Sparrow et al. 1987). Previous work on N. gonorrhoeae showed that galectin-3 binds the LPS 
α-chain composed of Glc, Lac, LNnT, and neolactohexaosyl (a derivative of neolactotetraosyl 
ceramide), the latter with higher affinity (John et al. 2002). This is consistent with galectin-3 
preferentially binding to poly-lactosaminylated substrates that are composed of ß1-3 linked 
LacNAc residues (Massa et al. 1993). 
110 
 
Meningococcal LPS differs from gonococcal LPS as its α-chain contains fewer 
saccharide residues: whileLNnT is present in the LPS from both species, in meningococcal 
LPS this group is attached to HepI via a Glc, and in the gonococcus there are GalNAc and Gal 
residues in addition (Fig. 1.3, A and B) (Yamasaki et al. 1999). 
The contribution of N. meningitidis LPS to galectin-3 binding was investigated using 
strains with defined mutations leading to truncation of the LPS molecule (provided byDr. 
Derek Hood, University of Oxford); this allowed assessment of the contribution of the 
individual saccharide units to galectin recruitment. Galectin-3 binding was examined to the 
wild-type strain MC58 and isogenic strains with mutations in genes encoding glycosyl 
transferases responsible for the addition of carbohydrates to the LPS molecule (Fig 1.3 A). 
The lgtA and lgtB mutants lack enzymes responsible for the biosynthesis of LacNAc, while 
the galE mutant lacks the LNnT structure (Jennings et al. 1995b); theicsBmutant lacks the 
gene encoding the enzyme responsible for the addition of glucose to HepI (van der Ley et al. 
1997) and the lsi-1 mutant lacks the gene encoding the enzyme responsible for the addition 
of HepII to HepI. However, mutation oflsi-1also affects the α-chain of LPS; this mutant also 
lacks the entire oligosaccharide portion except the first heptose (Jennings et al. 1995b).  
Initially, gel electrophoresis and silver staining was performed on LPS preparations 
from the mutants and the wild-type strains to confirm that they express truncated versions 
of LPS (Fig. 4.6, A). Migration of LPS was consistent with the effect of the mutations on the 
α- and β-chains of the molecule (Lesse et al. 1990). Analysis of galectin-3 binding to whole 
fixed N. meningitidis by flow cytometry demonstrated that all mutants expressing a 
truncated LPS molecule showed significantly reduced binding to galectin-3 compared to the 
wild-type strain (Fig. 4.6B and C,MC58ΔgalE p=0.0032, MC58ΔlgtAp=0.0076, 
MC58ΔlgtBp=0.0003, MC58Δlsi-1 p=0.0062, MC58ΔicsB p=0.0043), demonstrating that full 
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length LPS is required for galectin-3 binding to the meningococcal surface. As mutation of 
lgtB alone was sufficient to abolish galectin-3 binding, the terminal galactose and an intact 
LacNAc moiety are required for the interaction.   
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Figure 4.6 Meningococcal LPS is required for binding of galectin-3. 
(A) Silver staining of LPS preparations from strains MC58ΔicsB, MC58Δlsi, MC58ΔlgtB, 
MC58ΔlgtA, MC58ΔgalEand MC58. (B) Representative FACS tracing of the binding of 
galectin-3 (3.3 μM) to strains of N. meningitidis with full length (MC58) and truncated 
versions of LPS (MC58ΔgalE, MC58ΔlgtA, MC58ΔlgtB, MC58Δlsi andMC58ΔicsB, dotted black 
traces). (C) Quantification of binding of galectin-3 (3.3 μM) to strains of N. meningitidis with 
full length (MC58) and truncated versions of LPS. There was a significant reduction in the 
binding of galectin-3 to all strains with truncated LPS (MC58ΔgalEp=0.0032, 
MC58ΔlgtAp=0.0076, MC58ΔlgtBp=0.0003, MC58Δlsi-1 p=0.0062, MC58ΔicsB p=0.0043). 
Data are from four different experiments and error bars show the standard deviation. 
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4.4.3 Effect of sialic acid and LPS immunotype on binding to galectin-3 
N. meningitidis strain MC58 expresses L3,7,9 immunotype LPS which can be modified 
by the addition of an α2,3-linked sialic acid (Mandrell et al. 1991); an LPS specific sialyl 
transferase (Lst) is responsible for the linkage of sialic acid to the terminal galactose of the 
α-chain (Mandrell et al. 1990). Studies with glycan microarrays have demonstrated that the 
presence of sialic acid on terminal residues of glycans can inhibit binding of some galectins, 
although this did not affect galectin-3 (Ahmad et al. 2004b; Stowell et al. 2008b). To 
determine whether LPS sialylation alters galectin-3 binding to N. meningitidis, we compared 
the binding to wild-type strain MC58 and an isogenic mutant lacking lst. In parallel, to 
further understand the impact of sialic acid on galectin-3 binding to N. meningitidis, we also 
examined the effect of the presence of the polysaccharide capsule, which consists of α2,8-
linked polysialic acid. The gene siaD encodes the 2,8 polysialyl transferase required for 
capsule synthesis (Freiberger et al. 2007), while siaC is necessary for sialic acid biosynthesis 
(Edwards et al. 1994); therefore, MC58ΔsiaC is unable to express a capsule or sialylate its 
LPS without exogenous CMP-NANA. We analysed the effect of galectin-3 interaction with 
wild-type MC58 and isogenic mutant strains MC58ΔsiaD, MC58ΔsiaC, and MC58Δlst ((Exley 
et al. 2005) and Table 2.1). While there was no significant difference in galectin-3 binding to 
the strains, there was a consistent trend to increased binding to MC58ΔsiaC (Fig. 4.7, 
p=0.0671). 
Next, we chose a panel of disease causing isolates that belong to different 
serogroups and express different LPS immunotypes (Table 2.1), as shown by differences in 
the migration of LPS (Fig. 4.8 A). Analysis by flow cytometry demonstrated that, while there 
was some variation in the relative level of binding, strains belonging to different serogroups 
were able to bind galectin-3 (Fig. 4.8 B). Interestingly, all the strains which bind galectin-3 
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express an LPS immunotype containing LNnT and thus a terminal LacNAc. Z2491 is a 
serogroup A isolate which expresses an L9 immunotype LPS (Choudhury et al. 2008), while 
the serogroup B strains MC58 and H44/76 (Plested et al. 1999), the serogroup C strains 8013 
(Geoffroy et al. 2003) and FAM18 (this study, data not shown) all express L3,7,9 
immunotype LPS. The only strain which did not show similar binding of galectin-3 was 
F8238, a serogroup A isolate which expresses immunotype L10 LPS that is not thought to 
include LacNAc or LNnT moieties (Maslanka et al. 1997). 
Taken together, our data demonstrate that full length galectin-3 binds to the 
extracellular pathogen N. meningitidis and LPS on the bacterial surface is required for this 
interaction. Along with our observation that there is co-localisation of galectin-3 and N. 
meningitidis in tissue, exogenous galectin-3 secreted by immune cells could bind to bacteria 
during disseminated disease. Given the known oligomerisation and cross-linking properties 
of galectin-3 (Ahmad et al. 2004a), we hypothesised that this could affect the ability of 
bacteria to interact with host molecules and cells. 
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Figure 4.7 The effect of sialic acid on interaction of N. meningitidiswith galectin-3. 
Quantification of flow cytometric analysis of galectin-3 binding shows no significant 
difference in binding to the wild-type strain and a strain lacking LPS sialylation (MC58Δlst), 
or capsule (MC58ΔsiaD). A tendency to increased galectin-3 binding was detected to the 
strain lacking sialic acid (MC58ΔsiaC, p=0.0671). Data are from four different experiments 
performed in duplicate, and error bars show the standard deviation.  
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Figure 4.8 Galectin-3 binding to N. meningitidis is independent of serogroup. 
(A) Silver staining showing LPS forN. meningitidis clinical isolates. Bands are the different 
sizes of LPS, indicating various immunotypes. (B) Binding of galectin-3 to serogroups A, B, 
and C N. meningitidis. Fixed bacteria were incubated with 3.3 μM galectin-3 for 1 hr and 
binding was detected by flow cytometry. Galectin-3 binding to N. meningitidis strains F8238 
and Z2491 (serogroup A), MC58 and H44/76 (serogroup B), 8013 and FAM18 (serogroup C) 
demonstrates that binding is independent of serogroup. Interaction of the strain F8238 with 
galectin-3 is significantly reduced (**, Unpaired Student’s t-test, p=0.0098) compared to 
strain MC58. Binding is expressed as the Fluorescence Index. Data are from four 
independent experiments and error bars show the standard deviation.  
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4.5 Summary 
Work in this chapter characterised the binding of the meningococcus to galectin-3 
using N. meningitidis serogroup B MC58 and recombinant human galectins. Only the 
chimera-type galectin-3 was shown to bind N. meningitidis; therefore this interaction was 
analysed in detail. The interaction was dependent on meningococcal LPS (which contains 
the known galectin-3 ligand LacNAc) and the galectin-3 CRD, as lactose partially inhibits 
binding. However, almost complete loss of binding was also observed with only the CRD of 
galectin-3 demonstrating that, while this region is necessary for binding, it is not sufficient. 
This suggests that oligomerisation of galectin-3 might be important for interaction. No 
statistically significant effect on the interaction between galectin-3 and N. meningitidis was 
observed when sialic acid was removed from LPS. Moreover, meningococcal strains 
belonging to different serogroups are able to bind galectin-3, with LPS from all the strains 
which bound galectin-3 containing LacNAc, indicating that the interaction is dependent on 
the immunotype of the strain.  
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CHAPTER 5: Consequences of galectin-3 binding to N. 
meningitidis on interaction with cells 
 
5.1 Influence of galectin-3on bacteria-cell interaction 
Galectin-3 has diverse functions depending on its localisation. Intracellular galectin-3 
can regulate cell growth, differentiation and apoptosis, while extracellular galectin-3 has 
been implicated in cell adhesion and phagocytosis (Bornstein and Sage 2002; Melo et al. 
2011). Furthermore, secreted galectin-3, which is soluble and present serum and 
bronchoalveolar lavage fluid (Sano et al. 2000; Wanninger et al. 2011; Yilmaz et al. 2011; 
Taniguchi et al. 2012), can modulate inflammatory responses and bacterial uptake by 
neutrophils (Farnworth et al. 2008). Given the multiple regulatory effects of galectin-3 on 
cells and especially its influence on immune responses, this lectin is considered to be 
important during bacterial infection, and can have either a beneficial or detrimental effect 
on the infecting organism. Several functions have been attributed to galectin-3 during 
different infections and are mainly dependent on its extracellular location. For example, 
intracellular galectin-3 accumulates transiently in the vicinity of invading bacteria that lyse 
their vacuole and has been proposed as a marker of vacuole lysis for Gram positive and 
Gram negative bacteria, but no function has been defined in this context (Paz et al. 2010). 
On theother hand, cell surface galectin-3 enhances adhesion of H. pylorito human epithelial 
cells(Fowler et al. 2006a), while soluble galectin-3 may regulate the innate immune 
response against Rhodococcus equiby impairing IL-1β productionby macrophages (Ferraz et 
al. 2008). Moreover, galectin-3 is a negative regulator of LPS function during Salmonella 
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infection, as mice lacking galectin-3produce excessive pro-inflammatory cytokines and nitric 
oxide, and are more susceptible to LPS shock (Li et al. 2008).  
As demonstrated in the preceding chapters, galectin-3 levels increase in murine and 
human tissue following meningococcal infection, and N. meningitidis interacts with galectin-
3 via its LPS. Therefore in this chapter the potential consequences of this interaction were 
examined. 
As N. meningitidis replicates and disseminates in the bloodstream, where it 
encounters immune cells including phagocytes, we sought to examine the function of 
extracellular galectin-3, either in its surface-associated or soluble form, during phagocytosis. 
To analyse the effect of galectin-3 on cells, we used the THP-1 cell line and human primary 
monocytes obtained from the blood of healthy donors. Phagocytic assays were performed 
to evaluate the function of both endogenous and exogenous (added recombinant) galectin-
3 on bacterial association with cells and non-opsonic uptake. As meningococcal disease 
occurs soon after exposure of non-immune individuals to N. meningitidis, we studied 
bacterial uptake in the absence of human sera and antibodies. The effect of galectin-3 was 
also analysed by silencing the gene encoding this lectin in THP-1 macrophages, using siRNA 
and evaluating the ability of these cells to interact with bacteria. The effect of soluble 
galectin-3 was examined by pre-incubating bacteria with recombinant galectin-3 prior to 
incubation with THP-1 macrophages or human primary monocytes. 
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5.2 Intracellular survival of N. meningitidis in phagocytes 
An in vitro model, which allows the assessment of bacterial association with and 
internalisation into cells was initially established to analyse the interaction of N. meningitidis 
with cells. 
Monocytic cell lines such as THP-1 or U-937 have been widely used to investigate 
cellular differentiation (Tsuchiya et al. 1980; Estrella et al. 2011). These cells express 
characteristic markers of immature monocytes in suspension and differentiate into 
adherent macrophage-like cells by treatment with compounds including PMA(Kohro et al. 
2004). Differentiation can be monitored by changes in morphology, adherence, 
phagocytosis, surface markers, release of TNF-α and expression of specific genes (Maess et 
al. 2010). These parameters determine whether differentiated THP-1 cells have 
morphological and functional features of primary macrophages (Auwerx 1991; Schwende et 
al. 1996). Furthermore, these cells have been employed to study bacterial infection(Read et 
al. 1996; Kalmusova et al. 2000; Ramarao and Meyer 2001; Jack et al. 2005).  
Here differentiated THP-1 macrophages were challenged with N. meningitidis in the 
absence of human serum. Although bactericidal activity of human complement against N. 
meningitidis can confer protection against disease (Drogari-Apiranthitou et al. 2002), non-
opsonic uptake and intracellular killing of the bacterium by monocytes and macrophages 
have also been demonstrated (McNeil et al. 1994). In particular, phagocytosis of N. 
meningitidis in absence of complement has been attributed to the presence of phagocytic 
receptors on macrophages such as the SRs and siglecs, (Jones et al. 2003; Varin et al. 2010). 
Preliminary experiments were performed to optimisethe differentiationof THP-1 into 
macrophages (data not shown). PMA at a concentration of 100 µg/ml for 72 hours allowed 
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differentiation of 5x105 cells per well, which adhered to the surface of tissue culture flasks 
and underwent visible morphological changes. Differentiation was analysed by microscopy 
(to examine changes in cell shape), and by flow cytometry to examine the presence of 
surface receptors such as CD11b and CD18 (not shown) which are up-regulated during cell 
differentiation (Liu et al. 2008). 
Initial challenge of 5x105 cells per well for one hour allowed N. meningitidis to 
interact with cells which were then washed to remove unbound bacteria. To determine the 
total number of bacteria associated with cells (both the extracellular fraction bound to cells 
and the intracellular fraction), THP-1 macrophages were lysed with saponin and viable 
bacteria recovered by plating. To determine the number of bacteria which were internalised 
by macrophages, gentamicin (100µg/ml) was added for 15 minutesto cells to kill 
extracellular bacteria, and viable bacteria recovered (Vaudaux and Waldvogel 1979). 
Using N. meningitidis strain MC58 at different MOIs, we were able to demonstrate 
that THP-1 macrophages interact with meningococci depending on the number of bacteria 
(Fig.5.1 A and B); the total number of cell associated and internalised bacteria is 
proportional to the initial inoculum over a range of MOIs (10, 50, 100). For all subsequent 
experiments with THP-1 macrophages, an MOI of 30 was used. Next, the ability of THP-1 
macrophages to kill N. meningitidis was investigated by determining the number of 
intracellular bacteria at different time points after challenge. Cells were subjected to initial 
bacterial challenge for one hour, then gentamicin was added andcells incubated at 37°C for 
further time periods (60 and 180 minutes, Fig. 5.2) before bacteria were recovered.To 
establish whether bacterial recovery was dependent on uptake by the THP-1, control cells 
were treated with cytochalasin D (CCD), which prevents phagocytosis by interfering with 
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polymerisation of actin andimpairing cytoskeletalre-arrangements (Schliwa 1982; Bailly et 
al. 1991; Wakatsuki et al. 2001).  
Bacterial association with THP-1 macrophages increased over time in presence or 
absence of CCD (Fig. 5.2 A). As expected, the internalisation of bacteria is significantly 
higherin the absence of CCD (Fig. 5.2 B). Moreover, the number of intracellular bacteria 
decreases over time (Fig. 5.2 B), indicating that THP-1 macrophages efficiently kill 
meningococci.  
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Figure5.1 Association to and bacterial uptake by THP-1 macrophages. 
(A)Bacterial associationwith cellsshown as the total number of recovered from 2x105THP-1 
macrophages 1 hour afterchallenge with N. meningitidis MC58 at increasing MOIs. (B) The 
number of intracellular bacteria recovered from THP-1 macrophages 1 hour after challenge 
with different MOIs. Data are from one representative experiment; similar results were 
obtained on at least three occasions. Error bars show the standard deviation.  
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Figure 5.2 N. meningitidis is internalised and killed by THP-1 macrophages. 
The number of bacteria associated with (A) and internalised by (B) THP-1 macrophages 
shown as the percentage of bacteria in the inoculum. (A) Times are shown after an initial 1 
hour incubation in presence (squares) and absence (dots) of Cytochalasin D. (B) Gentamicin 
was added to cells to kill extracellular bacteria and bacteria recovered immediately (0 
minutes), or following incubation for a further hour (60 minutes) or three hours (180 
minutes). Data are from one representative experiment. Error bars indicate the standard 
deviation and the experiment wasrepeated on at least three occasions.  
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5.3 Role of endogenous galectin-3 on the association with or uptake of N. 
meningitidis by phagocytes 
As consistent association with and internalisation of N. meningitidis into THP-1 cells 
was observed, next we investigated the effect of galectin-3 on these processes. Given the 
role of endogenous galectin-3 in phagoctytosis of both IgG-opsonised erythrocytes and 
apoptotic cells in vitro and in vivo (Sano et al. 2003), the influence of endogenous galectin-3 
in THP-1 cells during interactions with N. meningitidis was evaluated. 
Knock-down of galectin-3 in THP-1 macrophages was achieved through transient 
silencing of the galectin-3 gene by transfection with small interfering RNAs (siRNA). Gene 
silencing was confirmed by western blot analysis (Fig. 5.3 A) and was reproducible on at 
least four occasions (not shown). 
The effect of galectin-3 on signaling by THP-1 cells following infection was analysedby 
measuring levels of TNF-α, a key pro-inflammatory cytokine (Schwende et al. 1996). This 
cytokine is markedly elevated during meningococcal disease (Deghmane et al. 2009). The 
production of TNF-α was significantly increased in cells infected with MC58 (Fig. 5.3 B); 
silencing of galectin-3 did not affect significantly the production of this cytokine, suggesting 
that THP-1 cells lacking galectin-3 are able to respond to bacteria by secreting pro-
inflammatory mediatiors. 
Additionally, bacterial association with and phagocytosis of N. meningitidis was 
examined using THP-1 macrophages transfected with galectin-3 siRNA or transfected 
without oligonucleotides (mock). Results show that knock-down of galectin-3 had no 
detectable effect on either the number of bacteria associated with cells or the number of 
internalised bacteria (Fig. 5.4 A and B, cell associated bacteria p=0.4739, internalised 
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bacteria p=0.3327). These data indicate that endogenous galectin-3 is not required for the 
binding and/or uptake of N. meningitidis by THP-1 macrophages.  
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Figure 5.3 Effect of galectin-3 silencing on THP-1 cells. 
(A) Analysis of siRNA mediated knockdown of galectin-3 by western blot. Similar levels of 
actin (50kDa) are observed in both mock treated cells (Mock) and siRNA treated cells (siRNA 
Gal3), while galectin-3 (30 kDa) was detected only inmock control cells. (B) Levels of TNF-α 
in supernatants of wild-type (Mock) or siRNAGal-3 cells (siRNA Gal3) uninfected or infected 
with N. meningitidis MC58 at an MOI of 30 (indicated).The levels of TNF-α increase 
significantly in both mock and siRNAGal-3 infected cells (mock cells p=0.0176, siRNAGal-3 
cells p=0.0039). Data are from one representative experiment performed in duplicate and 
error bars show the standard deviation. 
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Figure 5.4 Effect of endogenous galectin-3 on the interaction of N. meningitidis with THP-1 
macrophages. 
The interaction of meningococci with THP-1 macrophages is shown as the percentage of cell 
associated (A) or internalised bacteria (B) relative to the initial inoculum, with control (Mock, 
grey bar) and galectin-3 knock-down cells (siRNA Gal3, black bar).(A) Bacterial association 
with THP-1 macrophages after 1 hour of infection. No significant difference in bacterial 
association was seen (One tailed, paired Student’s t test, p=0.4739) (B).Bacterial 
internalisation by THP-1 macrophages after 1 hour of infection.There was no significant 
difference in bacterial internalisationin control or knock-down cells (One tailed, paired 
Student’st test, p=0.3327). Results are the mean of five different experiments and error bars 
show the standard deviation.  
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5.4 Role of exogenous galectin-3 in meningococcal infection 
5.4.1 Effect of exogenous galectin-3 on interactions of N. meningitidis with 
phagocytic cells 
Knock down of galectin-3 did not affect the adhesion or uptake of meningococci by 
THP-1 macrophages, suggesting that endogenous intracellular or cell surface galectin-3 is 
not required for phagocyte interactions with N. meningitidis. However, extracellular 
galectin-3 was demonstrated to associate with N. meningitidisby immunohistochemical 
analysis in Chapter Three, indicating that galectin-3 may interact with bacteria in the 
extracellular space.  
Therefore, as extracellular galectin-3 enhances phagocytosis of S. pneumoniae by 
murine neutrophils (Farnworth et al. 2008), we examined whether binding of exogenous 
galectin-3 to N. meningitidis prior to encounter with phagocytes influences the interaction 
between meningococci and these cells.  
THP-1 cells were differentiated into macrophages and challenged at an MOI of 30 for 
one hour with wild-type MC58 N. meningitidiswhich had been pre-incubated with 3.3 
μMgalectin-3 (a concentration at which binding is detected) or PBS. The number of cell 
associated and internalised bacteria was determined after one hour, and calculated as 
percentage relative to the inoculum. However, there was considerable variation in the 
number of cell associated bacteria in independent experiments. Therefore,the number of 
cell associated bacteria following pre-incubation with galectin-3 was normalised for values 
obtained without additional lectin (i.e.bacteria pre-incubated with PBS, shown as 100% in 
figures).A 1.6 fold increase in association was observed when meningococci were pre-
incubated with recombinant galectin-3 (Fig. 5.5 A, p=0.0201). In contrast, exogenous 
galectin-3 had no detectable effect on the internalisation of bacteria (p=0.1499Fig. 5.5 B).  
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To investigate whether galectin-3 has a similar effect with human primary 
monocytes, monocytic cells were isolated from PBMCs, as adherent cells (Fuss et al. 2009). 
The purity of monocytes was examined by fluorescence microscopy for their characteristic 
“kidney shape” of nuclei and the presence of CD14 (de Almeida et al. 2000; Mayer et al. 
2011). An MOI of 50 and 90 minutes of challenge with N. meningitidis were established as 
conditions for infection of human primary monocytes, in contrast to THP-1 macrophages 
which required a lower MOI and a shorter period of infection. 
Similar to THP-1 macrophages, a significant increase in bacterial association to 
monocytes was observed after pre-incubating MC58 with galectin-3 compared to controls 
(1.9 fold increase, Fig. 5.6 Ap=0.0002). The percentage of bacteria internalised by 
monocytes was comparable for bacteria pre-incubated with PBS or galectin-3 (Fig. 5.6 B), as 
observed with THP-1 macrophages. Taken together, these results demonstrate that 
exogenously added galectin-3 influences the association of bacteria to both macrophages 
and monocytes without affecting internalisation.  
To establish whether expression of bacterial LPS was required for the galectin-3-
mediated enhanced association of N. meningitidis to monocytes, binding of the MC58ΔlgtB 
strain, which does not to bind galectin-3 was examined (Fig. 5.6 C and D). First we examined 
whether changes in the LPS structure affect adherence of bacteria to the cell surface. As 
shown in Fig 5.6 C, loss of lgtB did not affect the association of bacteria with THP-1 
macrophages. We therefore compared the influence of exogenous galectin-3 on the 
association of MC58 and MC58ΔlgtB with macrophages. While there was a significant 
increase in the association of the wild-type strain to monocytes following pre-incubation 
with galectin-3 (Fig. 5.6 D, p=0.0249), exogenous galectin-3 had no effect on the adhesion of 
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MC58ΔlgtB (Fig. 5.6 D, p=0.2613), indicating that full length LPS is required for the galectin-3 
enhanced interaction of N. meningitidis with monocytes. 
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Figure 5.5 Exogenous galectin-3 promotes interaction of N. meningitidis with THP-1 
macrophages. 
(A) Association of meningococci to THP-1 macrophages analysed by bacterial recovery 
following infection of bacteria previously incubated with 3.3 μM galectin-3 (black bars) or 
PBS (grey bars). Bacterial association is shown as relative to the number in the inocula, and 
normalised to results obtained with bacteria pre-incubated with PBS (shown as 100%).  The 
association of bacteria pre-incubated with galectin-3 is significantly increased compared to 
bacteria pre-incubated with PBS (One-tailed paired Student’s t test, *p=0.0201). Data are 
from six experiments and error bars show the standard deviation. (B) Uptake of 
meningococci by THP-1 macrophages shown as the percentage of internalised bacteria 
relative to the inoculum. 
  
133 
 
 
 
Figure 5.6 Influence of exogenous galectin-3 on the interaction of N. meningitidis with 
human primary monocytes. 
(A) Association of N. meningitidiswith primary human monocytes following pre-incubation 
of MC58 with galectin-3 (3.3 μM) or PBS prior to infection for 90 mins. Bacterial association 
is shown as the percentage of bacteria associated to cells relative to bacteria in the inocula; 
results are normalised to bacteria pre-incubated with PBS (shown as 100%). Association of 
bacteria to cells in presence of galectin-3 is significantly higher than in absence of galectin-
3 (One-tailed paired Student’s t test, ***p=0.0002). Data are from five different 
experiments performed in duplicate, and error bars show the standard deviation. (B) 
Percentage of internalised bacteria relative to bacteria in the inoculum at 90 minutes post-
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challenge following pre-incubation with PBS (grey bar) or galectin-3 (black bar). (C) 
Percentage of MC58 andMC58ΔlgtB associated with primary monocytes relative to bacteria 
in the inoculum.Comparable levels of MC58 and MC58ΔlgtBare associated with cells. (D) 
Association of meningococci with human monocytes following pre-incubation of MC58 
(black bars) or MC58ΔlgtB (white bars) with galectin-3 or PBS. Bacterial association is 
shown as percentage of bacteria associated with cells relative to bacteria in the inocula; 
results are normalised to bacteria pre-incubated with PBS (shown as 100%). Association of 
MC58ΔlgtB is unaltered in presence or absence of galectin-3 in contrast to the wild-type 
strain, which shows a significantly increased adhesion to monocytes when pre-incubated 
with galectin-3 (One-tailed paired Student’s t test, *p=0.0249). Data are the mean of nine 
different experiments and error bars show the standard deviation.  
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5.4.2 Exogenous galectin-3 has no effect on adherence of meningococci to 
epithelial cells 
The finding that galectin-3 promotes the association of N. meningitidis with 
macrophages and monocytes prompted us to examine whether this phenomenon is 
observed with other cell types which express a different array of cell surface molecules. 
In the extracellular space, galectin-3 binds to a variety of extracellular matrix 
components like laminin, fibronectin and collagen IV (Nangia-Makker et al. 2008; Melo et al. 
2011). We used Detroit 562 cells, a human pharyngeal cell line which represents the first 
cellular barrier that N. meningitidis encounters when it colonises the human host.Detroit 
562 cells have been employed to study bacterial infections (Sanchez et al. 2011) and express 
receptors involved inN. meningitidis adherence, such as the tetraspanins CD9, CD63 and 
CD151 (Green et al. 2011). Other important receptors for adhesion of N. meningitdis to 
epithelial cells are CEACAMs, and Detroit 562 specifically express CEACAM1 on their surface 
((Ohannesian et al. 1995) and not shown). CEACAM-1 is also a receptor for galectin-3 on 
neutrophils (Feuk-Lagerstedt et al. 1999; Kuespert et al. 2011).  
Therefore, to investigate whether pre-incubation of N. meningitidiswith exogenous 
galectin-3 has an effect on bacterial interaction with epithelial cells, adhesion/invasion 
assays following procedures previously validated in the laboratory were performed. Detroit 
562 cells were challenged with N. meningitidispre-incubated with recombinant galectin-3 or 
PBS, using the procedure described for assays with phagocytes. To examine bacterial 
invasion, cells were treated with gentamicin to kill extracellular bacteria. In contrast to 
experiments with phagocytic cells, pre-incubation of bacteria with galectin-3 did not affect 
meningococcal association with or internalisation into Detroit 562 cells (Fig. 5.7). 
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Figure 5.7 Exogenous galectin-3 does not affect the interaction of N. meningitidis with 
epithelial cells. 
(A) Association of meningococci with Detroit 562 epithelial cells following pre-incubation of 
bacteria with 3.3 μM galectin-3 (black bars) or PBS (grey bars) prior to infection. Bacterial 
association is shown as percentage of bacteria associated to cells relative to bacteria in the 
inocula and results are normalised to bacteria pre-incubated with PBS (shown as 100%). (B) 
Meningococcal internalisation by Detroit-562 cells measured as a percentage of the 
inoculum. Bacteria were recovered following gentamicin treatment to kill extracellular 
bacteria. No significant difference in the percentage of bacterial association or 
internalisation was observed following pre-incubation with galectin-3. Data are the mean 
of three different experiments, and error bars indicate the standard deviation.      
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5.5 Summary 
In this chapter we analysed the possible functional consequences of endogenous and 
exogenous galectin-3 in meningococcal infection with particular interest in the interaction of 
the bacterium with cells.  
Silencing galectin-3 in THP-1 cells demonstrated that endogenous galectin-3 does not 
influence the association and internalisation of bacteria into macrophages. However, 
extracellular galectin-3 plays an important role in the interaction with cells. While 
exogenous galectin-3 does not influence interactions with epithelial cells, it promotes the 
attachment of bacteria to the surface of monocytes and macrophages; this is dependent on 
galectin-3 binding to bacteria via LPS, as no enhancement of attachment was observed 
when the lgtB mutant was pre-incubated with galectin-3. 
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CHAPTER 6: Discussion 
 
In this thesis, the interaction between N. meningitidis and galectins was studied. 
Galectins are host molecules formerly thought to bind only endogenous glycans and 
mediate developmental processes such as cell differentiation and apoptosis.More recently it 
has been increasingly recognised that galectins also function as molecules able to bind 
glycans on pathogenic micro-organisms (Vasta 2009). The importance of studying these 
lectins in microbial infection is supported by the observation that some galectins are up-
regulated in response to infection and can promote subversion of immune responses, with 
important consequences on the pathogenesis of infection (Vray et al. 2004). Furthermore, 
certain galectins such as galectin-4 and galectin-8 possess bactericidal activity, and may 
represent crucial effectors of innate immune responses.  
This work focuses on meningococcal disease, an infection caused by N. meningitidis, 
a commensal Gram negative bacterium of the human nasopharynx, but also an extracellular 
pathogen able to cause serious blood and CNS conditions (Gammelgaard et al. 2011). The 
outcomes of meningococcal infection may be devastating and can lead to neurological 
debility and death(Stephens et al. 2007); therefore a better understanding of the 
pathogenesis of this infection is urgently needed.  
Meningococcal infection occurs when bacteria reach the bloodstream and the 
presence of bacteria in the circulation causes an intense inflammatory reaction due to the 
presence of high levels of circulating LPS (Andersen 1989; Brandtzaeg et al. 1989b). 
Galectins are lectins which can be present inhuman fluids including serum and 
bronchoalveolar lavage fluids where they can bind to and interact with micro-organisms 
(Ochieng et al. 2004; Wang et al. 2005; Barrow et al. 2011). Given the importance of 
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inflammation in meningococcal disease and the recent focus on these proteins as mediators 
of inflammation and soluble PRRs, we analysed the interactions between galectins and the 
extracellular pathogen N. meningitidis. 
Meningococcal disease is characterised by bacterial dissemination to organs 
including the brain, lung, kidney, heart, liver and spleen ((Guarner et al. 2004) and not 
shown). Here we assessed the presence of galectins in murine and human tissues by 
immunohistochemistry, and found that levels of galectin-3 increase in tissues from mice and 
patients upon infection with N. meningitidis. 
We did not detect galectin-1 in tissues, although it shares some functions with 
galectin-3 in inflammatory responses (Almkvist and Karlsson 2004) and competes for the 
same cellular ligands (Kopitz et al. 2001). Lack of expression was also observed for another 
galectin, galectin-4, which has recently been proposed to contribute to the innate immune 
response to bacterial infection as it can bind the O-antigen of E. coli 086 resulting in 
bacterial lysis (Stowell et al. 2010). Of note, this lectin does not bind the meningococcus 
which does not express the O-antigen. All the reagents used to detect galectin-1 and 
galectin-4 havesuccessfully been used for immunohistochemistry in previous studies 
(Kaltner et al. 2002; Saussez et al. 2005; Lohr et al. 2007), so the failure to detect these 
lectins is unlikely to have resulted from a technical problem. However, positive control 
tissue, including kidney or cells of the respiratory tract, could have been used.Given the 
over-expression of galectin-3 during N. meningitidis disease, we decided to concentrate our 
analysis on this chimera-type galectin. 
We observed expression of galectin-3 in several tissuesfrom mice, and its presence in 
the CNS (in particular the cerebellum, meninges and choroid plexus) underlines the 
potential relevance of this protein in meningococcal infection, asthis bacterium can cause 
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meningitis. Little is known about galectin-3 expression during CNSinfection even though it 
has been foundin brain tumors (Park et al. 2008).  
Galectin-3 in the CNS seemed to be restricted to cells and was not obvious in the 
extracellular space. The exact localisation of bacteria at this site was not assessed in our 
samples, but it is possible that immune cells such as recruited macrophages, neutrophils or 
dendritic cells, as well as the inflammatory glial cells, might be responsible for the high 
expression of galectin-3 in the brain during meningococcal meningitis. 
Interestingly, in other tissues including the heart, liver, lung, pancreas and spleen, 
galectin-3 was detected in both intracellular and extracellular sites, especially in association 
with bacterial colonies; this suggested a possible direct interaction between the protein and 
bacteria.  
Next we showed that human, mouse and chickengalectin-3 binds to N. meningitidis 
serogroup B strain MC58 through a CRD-LPS dependentinteraction. These results are 
entirely consistent with the known reactivity of galectin-3 with LacNAc and LNnT 
(Seetharaman et al. 1998), components of meningococcal LPS (Plested et al. 1999).  
The observation that binding of galectin-3 to meningococci occurs at a relatively low 
concentration of galectin-3 (0.33-10 µM), while the concentration of lactose needed to 
inhibit the interaction is high (100 mM)is indicative of high avidityof this galectin 
withbacteria, likely due to pentamerisation of full length galectin (Ahmad et al. 2004b). 
Interestingly, N. meningitidis expresses high levels of LPS (Brandtzaeg et al. 2001) and this 
may be important in mediating reactivity to galectin-3.  
Binding was not detected to the truncated form of galectin-3, which is devoid of the 
N-terminal section that contributes to oligomerisation. Several lines of evidence indicate 
that multivalent oligomerisation is required for the biological function of galectin-3 (Woo et 
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al. 1991; Lukyanov et al. 2005; Fermino et al. 2011). Indeed, lectin-monosaccharide 
interactions are relatively weak, with a dissociation constant of 10-4 M. Galectin-3 
monomers are in equilibrium with higher oligomers in solution, while galectin-3 precipitates 
as a pentamer with multivalent oligosaccharides (Ahmad et al. 2004b). Therefore, initial 
binding of a galectin-3 monomer may be followed by recruitment of further 
moleculesforming a complex of multivalent interactions, with the functions of galectin-3 
dependent on both ligand cross-linking and self-oligomerisation. Our results support this 
hytopthesis as the involvement of the ND indicates that binding of galectin-3 to N. 
meningitidis is achieved through multivalent interactions with both itself and bacterial LPS 
molecules.  
Furthermore, in comparison with previous data (John et al. 2002), our experiments 
yield similar reactivity as seen for galectin-3 and N. gonorrhoeae; gonococcal LPS purified 
from 7.5x107 bacteria was boundby 300 μg/ml galectin-3,while we detected binding of 
2x107 bacteria to 10 to 300 μg/ml galectin-3 (from 0.33 to 10 μM).  
Of note, preliminary data (described in the Appendix chapter) suggested that 
galectin-3 was not the only galectin able to bind N. meningitidis. Our study showed that 
galectin-8 also binds N. meningitidis and indicates that the sialic acidcapsule on the surface 
of N. meningitidis may mask the ligand(s) for galectin-8 (Appendix 2). Moreover, the low 
level of galectin-1 binding toN. meningitidis seems to be due to the rapid oxidation of this 
lectin. In fact binding of galectin-1 to N. meningitidis was observed only when the lectin was 
treated with an irreversible alkylating agent that stabilises its structure (Appendix 1). 
However, these data have not been confirmed and further analyses are required to assess 
whether galectins other than galectin-3 could influence meningococcal infection and 
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whether they involve mechanisms dependent on the specific protein expression, 
concentration or localisation. 
We found that intact LPS is required for the interaction with galectin-3, as mutation 
of lgtB was sufficient to abolish binding. Although the lsi-1 mutant (lacking the enzyme 
responsible for synthesis of the α-chain) showed a significant reduction in galectin-3 
binding, this is likely due to the interdependence of synthesis of the α- and β-chains; there is 
no discernible β-chain extension in the lsi-1 mutant (Jennings et al. 1995a). The presence of 
the inner core may also be important for binding by allowing appropriate positioning or 
presentation of LPS and/or by supporting multiple interactions and galectin-3 
oligomerisation, as recently described for glycoprotein ligands of galectin-3 (Krzeminski et 
al. 2011). Importantly, since the homodimeric proto-type galectin-7 as well as the tandem-
repeat-type galectin-4 did not recognise the meningococcus, the mere presence of the 
LacNAc epitope (which is bound by all three galectins with similar ΔG-values (Dam et al. 
2002) does not predict binding, and indicates a specific interaction of galectin-3 with N. 
meningitidis. 
Meningococcal strains are classified into different immunotypes based on variations 
in LPS composition (Plested et al. 1999) with differences in both inner and outer core 
structures (Tsai et al. 1987). In agreement with this, we observed a correlation between LPS 
immunotype and galectin-3 binding. All strains which bound galectin-3 express an LPS 
immunotype containing LNnT; the only strain which did not show similar binding of galectin-
3 was F8238, a serogroup A isolate which expresses LPS immunotype L10 that is not thought 
to include the LacNAc and LNnT moieties (Maslanka et al. 1997). Interestingly, individual 
meningococcal strains have the potential to express alternative outer core structures 
through phase variation (Jennings et al. 1999; Berrington et al. 2002). For example, phase 
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variation leading to switching off expression of the lgtA gene results in loss of the LacNAc 
and LnNT structures and a switch from immunotype L3 to L8 (Jennings et al. 1995b). Our 
results using a defined LPS mutant lacking lgtA demonstrate that this phase variation event 
would abolish galectin-3 binding. Of note, L3,7,9 immunotype LPScan undergo sialylation 
which enhances serum resistance (Unkmeir et al. 2002),but further elucidation of the 
consequences of galectin-3 binding may reveal that the capacity to bind this lectin also 
confers a survival advantage to the meningococcus during infection. 
Modifications of meningococcal LPS such as sialylation might affect the ability of the 
bacteria to bind galectin-3, although we only found a trend to increased binding to an lst 
mutant compared with the wild-type strain. The presence of terminal sialic acid on cell 
surface glycans can inhibit the activity of some galectins. For example, the N-terminal CRD 
of galectin-9 which does not recognise α2,3-sialylated N-glycans (Solis et al. 2010), while 
α2,3- sialylation does not affect galectin-3 recognition of glycans (Stowell et al. 2008a). 
However, removal of the both sialic acid capsule and the terminal sialylation of LPS tended 
to increase binding of galectin-3 possibly due to an improved accessibility of galectin-3 to 
LPS, although this finding was not statistically significant. 
Given the ability of N. meningitidis to interact with galectin-3, we sought to 
determine the consequences of the interaction in meningococcal infection, in an attempt to 
assess whether it results in beneficial or detrimental effects for the pathogen.  
Lectin-carbohydrate interactions are a proposed mechanism of pathogen recognition 
and/or adherence to cells (Sato et al. 2009) as described for galectin-3 and several micro-
organisms (John et al. 2002; Fowler et al. 2006a; Stowell et al. 2010). Galectin-3 was initially 
identified as intracellular protein, mediating endogenous functions, but is also on the cell 
surface and in the extracellular space as a soluble protein (Hughes 1999). One of the 
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functions of galectin-3 is to promote adherence of parasites or bacteria to human cells; for 
example, exogenously added galectin-3 mediates T. cruzi adhesion to human coronary 
artery smooth muscle cells (Kleshchenko et al. 2004). 
N. meningitidis is an extracellular pathogen, but a key event in meningococcal 
infection is the interaction with host cells (Carbonnelle et al. 2006). N. meningitidis 
encounters different cell types from the state of colonisation to the onset of systemic 
disease. These include epithelial cells in the nasopharynx, resident macrophages in the 
submucosa or monocytes in the bloodstream (Corbett et al. 2004). Our IHC data 
demonstratepresence of galectin-3 in both intracellular and extracellular spaces, and we 
investigated the role of galectin-3 in both these locations. 
We found that the epithelial nasopharyngeal cells as well as THP-1 macrophages and 
monocytes express galectin-3. Although we did not detect changes in the expression of 
surface galectin-3 in both epithelial cells and phagocytesduring infection in vitro,we 
analysed the consequences of the bacteria-lectin interaction on the association of bacteria 
with different cell types. 
Galectin-3 expression has been demonstrated in human nasopharyngeal epithelial 
tissues (Saussez et al. 2008b) and is proposed to contribute to epithelial cell adhesion 
through interactions with extracellular matrix. Moreover, pathogens such as H. pylori and P. 
aeruginosa bind galectin-3 on the surface of epithelial cells, and galectin-3 has been 
proposed as a receptor for N.gonorrhoeae as it is constitutively expressed at the apical side 
of the non-ciliated fallopian tube cells which selectively bind gonococcus (John et al. 2002). 
We found that the protein is detectable on the surface of Detroit 562 cells and 
confocal microscopy indicated that galectin-3 co-localises with meningococci. It is therefore 
possible that galectin-3 on the surface of these cells could contribute to meningococcal 
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attachment. However our experiments did not address this directly; we found that pre-
incubation of bacteria with exogenous galectin-3 did not affect bacterial association to the 
cell surface, which may be expected if surface galectin-3 was the direct target for 
meningococcal LPS binding. To conclusively address the role of epithelial cell surface 
galectin-3 as a receptor for N. meningitidis more detailed studies using blocking antibodies 
for galectin-3 or siRNA are required. 
To investigate the role of galectin-3 in meningococcal interactions with phagocytic 
cells, we used differentiated THP-1 cells as a source of macrophage-like cells, and human 
primary monocytes obtained from healthy donors. Gene silencing by siRNA was employed 
to gain insights into galectin-3 function in adhesion/uptake. siRNA knock down of galectin-3 
in THP-1 macrophages did not alter their capacity to bind or phagocytose N. meningitidis, 
indicating that neither surface expressed nor intracellular galectin-3 is necessary for 
meningococcal recognition and uptake by macrophages.  
Galectin-3 accumulations have been described in macrophages infected with 
Shigella, Listeria and Mycobacteria (Beatty et al. 2002; Paz et al. 2010), but no function in 
phagocytosis of micro-organisms by macrophages have been attributed to galectin-3 to 
date.In contrast, exogenous galectin-3 has been shown to have a role in the phagocytosis of 
S. pneumoniae by neutrophils (Farnworth et al. 2008); therefore, we were interested to 
examine the role of exogenously added galectin-3 on bacterial-interaction with cells.  
A specific effect of recombinant exogenous galectin-3 was observed with N. 
meningitidis infection of phagocytes. Pre-incubation of N. meningitidiswith exogenous 
galectin-3 led to a significant increase in N. meningitidis interaction with monocytes and 
macrophages yet did not alter the number of internalised bacteria. This effect was 
dependent upon expression of full length LPS molecules which allow galectin-3 binding and 
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was not observed with Detroit 562 cells. However, the percentage of meningococcal 
adhesion and bacterial uptake relative to the initial inocula was only around 1% and 0.01% 
respectively, so differences in the internalised population may have been difficult to detect. 
Of note all experiments were performed in absence of opsonising antibodies, so the extent 
of interaction with cells might be due to the lack of opsonisation. Previous studies also 
conducted in absence of opsonisation showed relatively low levels of bacterial association 
to phagocytes (Jack et al. 2005; Casey et al. 2008). It has been reported that 30% of 
meningococci adhere to THP-1 macrophages and 1-2% of meningococci are internalised by 
macrophages when an MOI of 200 is used for infection, with an average of 0.1 internalised 
bacteria per cell (Casey et al. 2008). In our experiments, we used an MOI of 30 to infect THP-
1 macrophages and an MOI of 50 to infect human primary monocytes, and this might 
explain the low recovery of viable bacteria. Variability due to different technical procedures 
used might also influence the outcome of bacterial recovery. For this reason, the study of N. 
meningitidis phagocytosis could be undertaken using different techniques such as 
microscopy or FACS analysis in which fixed bacteria are used.  
Macrophages produce antimicrobial peptides which are released into the 
extracellular space and are responsible for extracellular killing (Zaiou 2007), while 
intracellular killing mechanisms include production of ROSand phagolysosomal activity (Dyet 
and Moir 2006). Therefore, the increase in N. meningitides on the surface of cells in the 
presence of galectin-3 might reflect increased adhesion or reduced killing; experiments with 
siRNA of THP-1 cells indicate that the effect of galectin-3 is on adherence to cells. 
It is possible that soluble galectin-3 binds N. meningitidis in the extracellular 
environment and cross links the bacterium to the surface of cells. The increased attachment 
of the meningococcus to the surface of macrophages and monocytes but not to epithelial 
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cells indicates a specific role restricted to phagocyte interactions and may be related to 
different composition of receptors known to recognise N. meningitidis. A multimeric 
interaction could lead to clustering of cell surface glycans and/or lectin-mediated binding to 
receptors for N. meningitidis. Galectin-3 may act indirectly by modulating the expression of 
non phagocytic receptors (not present on epithelial cells) and regulate their function. A 
relevant example is the ability of galectin-3 to inhibit T cell activation by promoting TCR 
down regulation (Chen et al. 2009). Known receptors implicated in meningococcal 
interaction with phagocytes include TLRs, macrophage receptor with collagenous structure 
(MARCO), SRs and siglecs (Jones et al. 2003; Pluddemann et al. 2009). Galectin-3 could 
modulate the expression of these receptors and increase bacterial association with cells or 
may induce re-positioning of these receptors allowing interaction with the bacterium. The 
hypothesis of galectin-3 modulating siglec-5, siglec-9 and SR-A was tested in preliminary 
studies (not shown), but no regulation of surface expression of these receptors was 
observed on addition of this lectin to THP-1 cells. However, other receptors involved in 
binding of N. meningitidis on phagocytic surface could be included, and the effect of 
galectin-3 on the conformation or location of receptors was not analysed. 
Ultimately, galectin-3 may indirectly affect adherence/uptake or interfere with TLR 
activation, given that LPS is a potent immune activator through TLR-4 dependent signalling 
(Zhang and Ghosh 2000). Previous experiments with Salmonella showed that galectin-3 is a 
negative regulator of LPS function (Li et al. 2008), but whether the binding to LPS is required 
for this regulation has not been investigated.  
Alternatively, it has been shown that pre-incubation of exogenous galectin-3 with 
purified LPS dramatically increases LPS binding to the surface of neutrophils (Fermino et al. 
2011). The authors propose that modification of LPS structure upon galectin binding or 
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oligomerisation crosslinks LPS receptors such as CD14 and TLR4 on the cells surface. 
Therefore we propose galectin-3 as a bacterial recognition molecule for N. meningitidis, but 
further studies are needed to fully elucidate the molecular basis of galectin-3 mediated 
interactions with cells and to investigate how this affects the host immune and 
inflammatory responses during infection.  
In summary, our work demonstrates that N. meningitidis interacts with galectin-3, a 
modulator of inflammation which has roles in many physiological and pathological 
conditions. We propose that this interaction could occur during meningococcal infection at 
sites where local concentrations of galectin-3, secreted by activated immune cells, 
accumulate and allow binding to the surface of bacteria. A consequence of this interaction 
would be the increased bacterial adhesion to the surface of phagocytes, which could 
eventually lead to enhanced meningococcal survival, for example by preventing 
phagocytosis or affecting the activity of the phagocyte through altered TLR ligand 
presentation.  
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6.1 Future studies 
Although confocal microscopy demonstrated the co-localisation of the 
meningococcus with endogenous galectin-3 on Detroit 562 epithelial cells, further studies 
are required to address whether this has consequences on bacterial adhesion. As discussed 
above, adhesion assays using blocking antibodies directed against galectin-3 or silencing 
galectin-3 expression in epithelial cells could be performed to directly address this.  
Our data suggest that increased bacterial attachment is dependent on the presence 
of full LPS on N. meningitidis. However, the mechanism of increased bacterial attachment to 
phagocytic cells needs to be elucidated. The role of possible phagocyte receptors involved in 
binding, and understanding whether recognise bacteria or galectin-3 could provide a more 
complete understanding of this phenomenon. Specific experiments would include confocal 
microscopy to visualise the presence and location of further knownreceptors for N. 
meningitidisor galectin-3 receptors. However, this would not exclude the possibility 
thatunknown receptors present on the cell surface are involved. 
The investigation of the influence of galectin-3 on innate immune responses to N. 
meningitidis is also important and has not been directly addressed in our study. Data on 
galectin-3 as a modulator of inflammation have been previously reported, and highlighted 
the potential role of galectin-3 as a key component in the host defence against microbes. 
Most in vivo data suggest a pro-inflammatory role for galectin-3 during acute inflammation, 
whereas it is implicated in resolution of inflammation during chronic infections (Ruas et al. 
2009). The specific functions of this lectin need to be investigated and vary enormously from 
one infection to another. For example, galectin-3 has been showed to be pro-inflammatory 
in Candida infections but mediates a Th2 response in Salmonella infection (Li et al. 
2008).Therefore, analysis of cytokine expression in galectin-3 knock down THP-1 
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macrophages could provide further insights into galectin-3 modulation of immune 
responses to N. meningitidis in human cells. 
In summary, more specific studies directed to analyse the role of endogenous 
galectin-3 during meningococcal infection would be required. Future work using galectin-3 
knock out animals will be performed to examine the role of endogenous galectin-3 during 
meningococcal disease. This could provide important insights into understanding the effects 
of galectin-3 on the pathology of infection in a broader context.  
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6.2 Conclusions and general considerations 
Many recent studies indicate that host galectins can represent novel PRRs able to 
target glycans on the surface of bacteria, viruses and parasites (Sato et al. 2009). Much is 
known aboutabout galectin binding specificity and affinity, but the majority of the 
carbohydrate ligands are yet to be identified, and studies of specific galectin-micro-
organism interactions are required. 
We show that N. meningitidis is able to interact with several galectins, and show that 
binding to galectin-3 enhances bacterial binding to phagocytic cells without increasing 
internalisation. This could enhance survival of the bacterium in the human host and 
represent another way for micro-organisms to disseminate, avoid intracellular killing and/or 
modulate host immune responses. 
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APPENDIX: Binding of galectin-1, -8 and -9 to N. meningitidis 
 
As galectin-3 interacts with N. meningitidis and influences phagocyte-bacteria 
interactions, the binding of other galectins to the bacterium was also assessed. In chapter 4, 
no evidence was found for an interaction between the meningococcus and galectin-1 -4 and 
-7. Preliminary data (i.e. experiments performed on a single occasion only) were obtained 
for interactionsof further galectins belonging to different families and N. meningitidis. 
Specifically, binding of N. meningitidis MC58 strain to modified galectin-1, galectin-8 and 
galectin-9 was investigated. These galectins have been studied in the context of different 
infections and several of their roles have been identified. For example, galectin-1 interacts 
with influenza virus and HIV-1 (St-Pierre et al. 2011; Yang et al. 2011); galectin-8 has 
microbicidal activity, as it recognises and kills blood group antigen-bearing pathogens by 
altering membrane integrity (Stowell et al. 2010), while galectin-9 acceleratesKlebsiella 
pneumoniae infection by reducing levels of IL-17 (Wang et al. 2011). 
All these galectins can be released into the extracellular compartment in response to 
inflammation,hence galectin recognition of potential meningococcal ligands could influence 
the pathogenesis of disease.  
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Appendix 1 Binding of N. meningitidis to galectin-1 
Galectin-1 is a member of the proto-type galectins, a homo-dimer formed by two 
identical CRDs linked together. Similar to other galectins, it has several biological functions, 
including the ability to stimulate cell growth, induce apoptosis and activation of human T 
cells (Sanford and Harris-Hooker 1990; Perillo et al. 1995; Pace et al. 1999; Galvan et al. 
2000). Furthermore, galectin-1 regulates leukocyte turnover by inducing exposure of 
phosphatidyl serine (PS) on the surface of neutrophils (Dias-Baruffi et al. 2003); the full 
length protein is required for this function, as a mutant C2S within the dimerization 
interface (the linker region between two CRDs of the protein) impairs galectin-1 
dimerisation and also fails to induce PS exposure (Dias-Baruffi et al. 2003). In addition, 
galectin-1 can be inactivated by oxidation which induces formation of three disulphide 
bonds that interfere with ligand binding (Stowell et al. 2009b). 
Results (in chapter four) showed that galectin-1 is does not bind N. meningitidis, 
suggesting that N. meningitidis does not express ligands for galectin-1, or that potential 
oxidation of this galectin prevents binding. Therefore we investigated binding of N. 
meningitidis to forms of galectin-1 that were stabilised by treatment with alkylating agents, 
DTT or IAA, to prevent oxidative damage (Stowell et al. 2009a). IAA covalently binds the 
thiol group of cysteine preventing the formation of disulphide bonds, while DTT is a 
reducing agent able to form a six-membered ring with an internal disulphide bond.  
In addition, a form of galectin-1, C2S, which contains a point mutation in the dimer 
interface was used in binding assays. The mutant C2S contains a sulphydryl group 
substituted with a hydroxyl group, and this stabilises the sugar binding activity in the 
absence of reducing agents (Stowell et al. 2009a). 
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A concentration of 3 µM of galectin-1 was used for experiments, as the minimum 
concentration required for binding to its ligands is 1.25 µM (Earl et al. 2010). Galectins were 
provided by Professor Gabius and treatment of recombinant galectin-1 with DTT and IAA 
were performed as previously described (Stowell et al. 2009a).Our results show that 
galectin-1 binds N. meningitidis only when treated with DTT (Fig. A.1), but not with IAA. DTT 
and IAA are both alkylating agents, and should bothstabilise the protein; however, only DTT 
is an irreversible alkylating agent as it reduces disulfide bonds (Lindstrom et al. 1973). Of 
note, the C2S mutant version of galectin-1 did not bind the meningococcus (Fig. A.1). 
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Figure A.1 Binding of recombinant human galectin-1 to N. meningitidis. 
Quantification offlow cytometry analysis of galectin-1 (Gal-1), galectin-3 (Gal-3), IAA treated 
galectin-1 (IAA Gal-1), DTT treated galectin-1 (DTT Gal-1) and C2S mutant of galectin-1 (C2S 
Gal-1) binding to N. meningitidis. N. meningitidis binds galectin-1 only when oxidation is 
prevented by DTT treatment, while it does not bind galectin-1 when it is mutated in the C2S 
region or when treated with IAA. Galectin-3 was used as positive control.  
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Appendix 2 Binding of N. meningitidis to galectin-8 
Galectin-8 belongs to the tandem-repeat galectins, and is secreted into the 
extracellular space where binds diverse ligands, especially glycoproteins such as integrins 
(Patnaik et al. 2006). It is involved in the regulation of cell adhesion, growth and 
differentiation (Bidon et al. 2001), and signalling of responses in leukocyte populations, 
although the contribution of each CRD remains unknown (Stowell et al. 2008b). Galectin-8 
has also been studied in infections and has been recently identified as a danger receptor for 
Salmonella invasion, as it binds host glycans present on damaged Salmonella-containing 
vacuoles and restricts bacterial replication (Thurston et al. 2012). 
Galectin-8 exists as a monomer of two CRDs that provides differential glycan binding 
specificity (Barondes et al. 1994; Hadari et al. 1995; Leffler et al. 2004). The specific ligands 
of galectin-8 include Neu5Acα2→3Galβ1→4Glc (Carlsson et al. 2007), where the sialic acid is 
attached on the galactose in a 2,3linkage (Ideo et al. 2003). The terminal galactose of the 
outer core of N. meningitidis LPS expressed by MC58 can be α2,3-sialylated through the 
action of Lst (Gilbert et al. 1996). Therefore we hypothesised a possible interaction between 
galectin-8 and MC58 (Tsai and Civin 1991).  
Binding assays were performed using 3µM full length human galectin-8 or its N-
terminal CRD, with fixed N. meningitidis MC58 or strains lacking sialic acid (MC58ΔsiaC) or 
capsular polysaccharide (MC58ΔsiaD). Galectin-8 binding to wild-type MC58 was detected, 
although there was no significant difference in binding of full length and ND galectin-8 (Fig. 
A.2, A). Moreover, increased binding was observed with the MC58ΔsiaD mutant compared 
to MC58 (Fig. A.2, B), indicating that loss of the capsule might enhance the accessibility of 
meningococcal ligands for galectin-8. However, MC58ΔsiaC strain does not show the same 
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effect, suggesting that bacteria might not be able to sialylate their LPS and and that α-2,3-
sialylation of meningococcal LPS is important for galectin-8 recognition. The extent of 
sialylation of MC58 LPS was not assessed in these experiments, and binding to MC58Δlst 
was not assessed due to these constraints.  
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Figure A.2Binding of recombinant human galectin-8 to N. meningitidis. 
(A) Flow cytometric quantification of galectin-8 binding to MC58 shows no significant 
difference in binding of full length galectin-8 (FL-Gal-8) and the N-terminal CRD of galectin-8 
(N-terminal Gal-8). (B) Flow cytometric quantification of galectin-8 binding to N. 
meningitidis showing increased binding of MC58ΔsiaD (siaD) to galectin-8.  
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Appendix 3 Binding of N. meningitidis to galectin-9 
Galectin-9 belongs to the tandem-repeat galectins and regulates many biological 
functions (Hirashima et al. 2004). It is formed by two distinct CRDs joined by a flexible 
peptide linker; the N-terminal CRD and the C-terminal CRD share only 39% identity, bind 
different sets of saccharides, and display different activities (Tureci et al. 1997; Li et al. 
2011). Evidence indicates that the C-terminalCRD is more potent in activating dendritic cells 
and inducing cell death than the N-terminal CRD (Li et al. 2011).  
Galectin-9 recognises T cell surface glycoprotein receptors such as Tim-3 and CD44 
(Sanchez-Fueyo et al. 2003; Katoh et al. 2007; Hastings et al. 2009). Binding of galectin-9 
toTim-3on activated Th1 and Th17 cells influences adaptive immunity and progression of 
autoimmune diseases (Li et al. 2011). Moreover, this lectin has been proposed to be an 
important regulator of infectious diseases, as it enhances survival of K. pneumoniae infected 
mice by decreasing lung bacterial clearance (Wang et al. 2011).  
Binding assays with 3 µM recombinant full length or N-terminal CRD of galectin-9 and 
fixed N. meningitidis showed that both the full length galectin-9 and the N-terminal CRD 
galectin-9 bind to N. meningitidis (Fig. A.3), although the consequences of this interaction 
were not addressed in this study. 
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Figure A.3 Binding of recombinant human galectin-9 to N. meningitidis. 
Quantification of flow cytometry analysis of full length galectin-9 (Full length) or N-terminal 
CRD of galectin-9 (N-terminal) binding following incubation of fixed MC58. N. meningitidis 
binds both full length and ND galectin-9.Binding is expressed as the fluorescence index.  
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Summary 
The work in the Appendix describes preliminary data on the binding of 
meningococcus to further human galectins, examined by flow cytometry using fixed whole 
N. meningitidis, serogroup B strain MC58.  
We show that N. meningitidis binds the form of galectin-1 stabilised with the 
irreversible alkylating agent DTT which does not undergo oxidation and retains its binding 
ability; however, galectin-1 stabilised with IAA and the mutant of galectin-1 in its linker 
region (C2S) do not interact with bacteria. Furthermore, galectin-8 binding to N. 
meningitidis is observed to be similar for both wild-type strains and strains lacking sialic acid 
on their surface, suggesting that sialic acid may not influence the interaction. In addition, 
binding of full length and ND galectin-9 to N. meningitidis was observed, indicating that ND 
is responsible for interaction.  
In conclusion, we observe an interaction between meningococci and different 
galectins belonging to different galectin groups, but the experiments were not repeated and 
the consequences of these interactions have not been investigated. 
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